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Chapter 1: General Introduction
1.1. Human liver anatomy
1.1.1. Liver anatomy and main functions
The liver is the largest organ in the human body and is located in the upper right
abdomen1. The liver contributes to the maintenance of the homeostasis and
metabolism in the organism2 and filters the blood from the digestive tract before it
is delivered to the systemic circulation. Furthermore, the liver metabolises drugs
and detoxifies chemicals while producing several vital molecules such as blood-
clotting proteins and bile. In addition, the liver accumulate glycogen as energy
store and has a key role in protecting the body from foreign antigens and gut-
derived1,2 microbes.
1.1.2. Liver cell types and liver Extra Cellular Matrix (ECM)
The main cell type in the liver are hepatocytes, or liver parenchymal cells, that
constitute up to 80% of the entire liver mass carrying out most of the hepatic
functions3. The remaining 20% of the liver mass is characterized by non-
parenchymal cells (NPCs) and namely Hepatic Stellate Cells (HSC), Liver
Sinusoidal Endothelial Cells (LSECs), Kupffer cells, and different types of
immune cells (e.g. natural killer cells) 4.
The different cell types of the liver are organised within the microvascular unit,
named sinusoid. The sub-endothelial space of Disse divides the epithelium
(hepatocytes) from the sinusoidal endothelium. In normal liver this space is
characterized by basement-membrane matrix, although it has a higher capability
of exchanging nutrients compared to other basement membrane. This key feature
allows the maintenance of the differentiated function of hepatic cells. During liver
16
fibrosis, the composition of hepatic ECM is dramatically affected both at
qualitative and quantity level. Indeed, the amount of ECM proteins increases 3-5
fold and the basement membrane is characterized by increased density composed
of fibrillary collagens (Figure 1.1)5.
The different NPC have a distinct and specific role in addition to providing
support to the specialised work of liver parenchymal cells. Hepatic Stellate Cells,
liver specific pericytes, store Vitamin A and play an essential role in the
physiology of the space of Disse where they are located 6. In response to liver
injury HSC undergo a phenotypic transformation from “quiescent” cells (non-
proliferating and non-contractile), into “activated” cells characterized by markedly
increased cell proliferation, contractility and increased secretion of extracellular
matrix (ECM)7,8. Accordingly, HSC are considered the key cellular effectors of
liver fibrogenesis following chronic tissue injury5,8,9.
The hepatic ECM is mainly composed by fibronectin, collagen type I, and
minimal amounts of collagen type III, IV, V, and VI10. The liver ECM, in its
biochemical and biomechanical integrity, has a critical role in maintaining the
healthy phenotype of both hepatocytes and NPCs10. It is evident that the
progressive changes in the composition and 3D structure of the liver ECM
occurring in chronic fibrogenic disorders of the liver markedly affect the biology
of hepatocytes, cholangiocytes and NPCs and ultimately represent key factors
towards the evolution to liver cirrhosis11,12.
Figure 1.1 Scheme of a healthy liver sinusoid where hepatic stellate cells (HSC), residing
within the Disse Space between sinusoidal endothelial cells (LSECs) and hepatocytes;
store retinoids within lipid droplets. (D) Upon liver injury, stellate cells become activated
17
and secret higher levels of extracellular matrix (ECM) proteins. Image modified from
Friedman et al 20045
1.2. Chronic liver diseases (CLD) evolving to cirrhosis and potentially
requiring liver transplantation
Liver disease affects almost 2 million people in UK13. Most liver diseases have a
chronic fibrogenic evolution leading to an advanced stage commonly defined as
cirrhosis. Cirrhosis is defined as a pathological stage characterised by the
accumulation of fibrillar ECM and by a marked alteration of the vascular
architecture of the liver with the establishment of abnormal communications
between the portal system and the hepatic veins associated with a marked
arterialisation of the liver tissue14. These changes lead to the development of
portal hypertension which is the main cause of the clinical complications of
cirrhosis leading to end stage liver disease. More than 4,000 people in the UK die
each year from cirrhosis. The most common chronic fibrogenic liver diseases
potentially leading to cirrhosis and liver failure are:
1. Chronic viral hepatitis due to a chronic hepatitis B or C virus infection.
HBV is the most common among those hepatitis viruses that cause chronic
infections of the liver in humans, and it represents a global public health problem.
Chronic hepatitis caused by HBV is the leading cause of cirrhosis worldwide and
approximately one-quarter of patients with cirrhosis develops decompensated liver
disease within 5 years15,16. In addition, chronic HBV infection is the major cause
of HCC worldwide17. Approximately 15 million of the estimated 350 million
individuals with chronic HBV infection have evidence of exposure to hepatitis D
(delta) virus (HDV), which requires hepatitis B surface antigen for transmission
and packaging18. HBV/HDV co-infection is associated with more severe acute
hepatitis and higher mortality than acute HBV mono-infection. Chronic co-
infection is clearly associated with a higher risk of cirrhosis and decompensated
liver disease. Hepatitis B and all of the complications resulting from it, as well
HDV and its complications, are globally preventable by hepatitis B vaccination,
18
and therefore elimination of HBV transmission and of new acute and chronic
infections appear to be a feasible goal.
Worldwide, an estimated 130–170 million people have HCV infection19,20.
Differences in past HCV incidence and current HCV prevalence, together with the
generally protracted nature of HCV disease progression, has led to considerable
diversity in the burden of advanced liver disease in different countries around the
globe. Morbidity and mortality rates from chronic HCV infection will increase
because the infection incidence peaked in the mid-1980s and because the liver
disease progresses slowly and is clinically silent to cirrhosis and end-stage-liver
disease over a 15-20 year time period for 15%-20% of chronically infected
individuals. About 75% of patients infected by HCV will develop a chronic HCV
infection and are subsequently at risk of progression to hepatic fibrosis, cirrhosis
and HCC21. Chronic hepatitis C generally progresses slowly in the initial two
decades, but can be accelerated during this time as a result of advancing age and
co-factors such as heavy alcohol intake, HIV co-infection, obesity/diabetes and
hereditary haemocromatosis22
2. Non-alcoholic fatty liver disease (NAFLD). In the UK as well as in other
industrialised Countries, it is estimated that 20-30% of the population is affected
by NAFLD23. NAFLD can range from a condition defined as “simple fatty liver”
characterised by triglyceride vacuoles accumulation in hepatocytes to a condition
defined non-alcoholic steatohepatitis (NASH) branded by the presence of cell
necrosis, inflammation and progressive fibrosis leading to the development of
cirrhosis. Five to 20% of patients with NAFLD develop NASH, which undergoes a
further transition to higher-grade fibrosis in 10% to 20% of cases24. In fewer than
5% of cases, fibrosis progresses to cirrhosis. These approximate figures lead to an
estimate of 0.05% to 0.3% for the prevalence of cirrhosis in the general
population. Moreover, NAFLD can progress to hepatocellular carcinoma also in
the absence of apparent cirrhosis21,25. In general NAFLD and NASH are
associated with other clinical manifestations of the so-called “metabolic
syndrome” (insulin resistance, dislypidemia, and high blood pressure). NASH is
predicted to become the leading cause of liver transplantation in the USA and
likely in Europe by the year 202024. The increasing burden of NAFLD and the
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current lack of effective treatments to halt or reverse disease progression in
patients with NASH have led to intense investigation into the basic mechanisms
involved in the development and progression of the disease. The most accepted
concept outlining the pathogenesis of NAFLD implies the occurrence of parallel
events (‘hits’) that involve a complex interaction and crosstalk between
environmental factors, host genetics and gut microflora26. This interaction might
promote isolated steatosis, cell death or progressive liver damage, innate immune
activation, inflammation and fibrosis.
3. Alcoholic liver disease (ALD). Liver damage and fibrosis due to excessive
consumption of alcohol are one of the most common causes of cirrhosis and liver
failure in the UK. Incidence rates of ALD in the UK have increased
alarmingly in recent years with death rates rising from 3,236 in 2002 to
4,400 in 200827. The association between alcohol intake and alcoholic liver
disease has been well documented, although cirrhosis of the liver develops in only
a relatively small proportion of heavy drinkers28. The risk of cirrhosis increases
proportionally with consumption of more than 30 g of alcohol per day, and the
highest risk is associated with consumption of more than 120 g per day28.
Similarly to NAFLD, the pathological manifestations of ALD range from
simple fatty accumulation in hepatocytes, to marked cell necrosis
associated to inflammation and fibrosis (i.e. alcoholic steatohepatitis:
ASH) to full blown cirrhosis. Importantly, the clinical course of ALD is
characterized by frequent episodes of acute on chronic damage or even
episodes of frank acute liver failure that represent an important
emergency in hepatology.
4. Other chronic liver diseases. Other less common chronic liver diseases
characterised by fibrogenic progression and evolution to cirrhosis are autoimmune
hepatitis (AIH), primary biliary cholangitis (PBC, previously defined primary
biliary cirrhosis) and primary sclerosing cholangitis (PSC). Autoimmune hepatitis
is a chronic inflammatory disease of the liver that occurs worldwide with a low
but probably underestimated prevalence. Although AIH typically affects young
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and middle-aged women, it can occur in both sexes and across all age groups29.
Prognosis of severe AIH is poor if untreated. The pathogenesis is complex,
combining environmental factors (external chemical or infectious triggers) and
host genetic susceptibility. Primary biliary cirrhosis is a chronic, progressive,
cholestatic, organ-specific autoimmune disease of unknown aetiology. It
predominantly affects middle-aged women, and is characterized by autoimmune-
mediated destruction of small- and medium-size intrahepatic bile ducts, portal
inflammation and progressive scarring, which without proper treatment can
ultimately lead to biliary fibrosis and hepatic failure. Currently, it is believed that
PBC is likely to be triggered by a combination of environmental factors including
infection in a genetically susceptible individual30,31. Primary sclerosing
cholangitis is a chronic cholestatic disease of the liver that is characterized by
progressive inflammation, fibrosis, and stricturing of the intrahepatic and
extrahepatic bile ducts leading to cirrhosis32. PSC likely, which occurs in
genetically susceptible individuals, perhaps after exposure to environmental
triggers, is a rare disease, mostly affecting people of northern European descent,
males greater than females. Inflammatory bowel disease (IBD) is present in ~75%
of the patients with PSC, mostly ulcerative colitis (~85% of the cases). In addition
to biliary fibrosis and cirrhosis, complications of PSC include dominant strictures
of the bile ducts, cholangitis, and cholangiocarcinoma.
Aetiology-dependent fibrogenic patterns of evolution to cirrhosis. It is
increasingly clear that different CLD are characterised by different predominant
pro-fibrogenic mechanisms and, while cirrhosis is the common result of
progressive fibrogenesis, there are distinct patterns of fibrosis development in
different and even within the same CLD. These aetiology-related patterns are
linked to the relative prevalence of different pro-fibrogenic mechanisms, such as
the activation of a chronic wound healing reaction, oxidative stress and
derangement of the epithelial-stromal equilibrium around bile ducts. The pattern
of fibrosis development typical of chronic viral hepatitis or of autoimmune
hepatitis is considered the results of portal-central (vein) bridging necrosis, thus
originating portal-central septa. In addition, this form of fibrogenic evolution is
characterized by the presence of “interface” hepatitis and development of portal to
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portal septa and septa ending blind in the parenchyma, and by rapid derangement
of the vascular connections with the portal system (early portal hypertension)34.
Chronic viral hepatitis and autoimmune hepatitis are characterized primarily by
chronic hepatocellular necrosis and apoptosis. Consequently, the main drive of
fibrogenesis is a typical chronic would healing reaction. This process, which is
highly efficient in the presence of single acute tissue insult, leads to progressive
scarring when tissue damage is chronic. In other words, deposition of fibrillar
matrix rather than organized tissue regeneration becomes the best option in order
to maintain tissue continuity. In addition to chronic hepatocellular necrosis and
apoptosis, hepatic fibrogenesis due to the chronic activation of the wound healing
reaction is characterized by the following key features: 1) a complex
inflammatory infiltrate including mononuclear cells and immunocompetent cells;
2) the activation of different types of ECM-producing cells (HSC, portal
myofibroblasts, etc.) with marked proliferative, synthetic and contractile features;
and 3) marked changes in the quality and quantity of the hepatic ECM associated
with very limited or absent possibilities of remodeling and regeneration33,34.
The general pathological features of liver fibrosis developing in ASH and NASH
are very similar, if not indistinguishable. Typically, fibrosis is initially limited to
lobular zone 3 and is concentrated around the sinusoids (capillarization) and
around groups of hepatocytes (chicken-wire pattern) on a general background of
hepatocellular steatosis/ballooning with different degrees of lobular inflammation.
This pericellular fibrosis eventually forms septa isolating regenerating nodules
leading to a picture typical of cirrhosis. Although the mechanisms underlying
fibrosis in ALD and NAFLD are in part common to those observed in other
chronic liver diseases (“core pathways” of hepatic fibrogenesis), there are specific
“regulatory pathways” for ASH and NASH. In both conditions, oxidative stress-
induced inflammation and fibrosis play a central role in the progression of the
disease35. In alcoholic liver injury, for example, acetaldehyde, the main metabolite
of ethanol, is able to increase gene transcription and synthesis of different ECM
components in activated hepatic stellate cells (HSC)36. In addition to acetaldehyde,
products of lipid peroxidation generated by exposure to ethanol or the production
of iron overload may also perpetuate HSC activation. Along these lines,
stimulation of lipid peroxidation or exposure to 4-hydroxynonenal (4-HNE), a
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highly reactive aldehydic end-product of lipid peroxidation, increases procollagen
I gene expression in activated human HSC37,38.
The difference in the patterns of evolution underlines the prevalence of different
fibrogenic mechanisms and different cellular effectors of fibrogenesis.
Accordingly, the natural history of disease associated with a cirrhotic liver caused
by chronic alcohol abuse could be markedly different when compared to a
cirrhotic liver caused by chronic viral hepatitis. The knowledge of these aspects
of the pathophysiology of CLD leads to the awareness that a correct interpretation
of the development of cirrhosis should take into consideration the correlation
between time of progression of liver disease, the aetiological agents, the dynamics
of the necro-inflammatory infiltrate, the distribution of fibrosis and the onset and
progression of portal hypertension depending on the aetiological agent39.
Hepatocellular carcinoma (HCC). Hepatocellular carcinoma represents a
frequent complication of cirrhosis and more than 4,000 new cases are diagnosed
each year in the UK40. As for any other type of cancer, the mechanisms leading to
HCC are characterised by mutations of the genes regulating cell replication and
the relationship between cells and the surrounding microenvironment. These
mutations are amplified in number and occurrence since the liver has a natural
tendency to regenerate and the presence of chronic damage leads to a continuous
regenerative stimulus. For this reason, a large proportion of patients with cirrhosis
develop HCC during the long clinical course of chronic hepatitis and cirrhosis.
The most radical treatments for HCC are represented by liver transplantation that
resolves also the underlying cirrhosis, and the surgical resection of the tumour. In
patients who are not candidates for liver transplantation or resection, tumor
ablation can be offered to extend life and to potentially downstage the tumor to
permit transplantation or resection.
1.3. The treatment of end-stage liver diseases: need for new treatment
strategies
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As previously mentioned , liver disease is currently the 5th most common cause of
death in UK41. Unfortunately, liver transplantation is the only effective treatment
for patients with end-stage liver disease42 but it is limited by both high cost and
severe shortage of donor organs. Indeed, almost 11,575 patients die each year in
the UK while waiting for a liver transplant43.
Thus, there is an unmet need to develop new treatments for liver diseases as a
potential alternative to donor-liver transplantation.
1.4. Tissue engineering of the liver
Over the last decades several studies have demonstrated the suitability of
techniques enabling to the decellularisation of human and animal tissues thus
providing the basis for tissue engineering employing naturally occurring ECM
scaffolds. In this context, liver bioengineering has potential for transplantations
and for toxicity testing during preclinical drug development. There is indeed
convincing experimental evidence that “Decellularisation-Recellularisation”
technologies provide a valuable platform for liver bioengineering through the
repopulation of a liver ECM scaffold with appropriate parenchymal and non-
parenchymal liver cells.
In 2010, Shupe et al. firstly reported the methodology for the decellularisation of
rodent livers highlighting the need of employing SDS in the decellularisation
process to effectively remove any cellular components, specifically DNA44.
During the same period, Uygun et al. described an efficient perfusion-
decellularisation method able to successfully preserve the vascular network. The
acellular translucent scaffold was then infused with rat-derived hepatocytes
through perfusion of the portal vein. Approximately 12.5 million of cells were
introduced during each of the four steps repeated at ten-minute intervals. The
recellularised grafts were maintained in a perfusion chamber for up to 2 weeks in
vitro. This was the first report providing evidence of the level of functionality of
the hepatocytes grown on a decellularised 3D ECM scaffold45.
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The report by Baptista et al. firstly demonstrated the possibility of repopulating
decellularised pig right lobes with human hepatocyte progenitors46. Subsequently,
Barakat et al developed a method to decellularise whole porcine livers, to be
repopulated with human cells with the goal of producing a clinically relevant
model of liver bioengineering. Foetal hepatocytes co-cultured with foetal stellate
cells were seeded within the pig liver ECM scaffold and the constructs were
perfused up to 13 days. Liver organoids showed active metabolism and preserved
capability to synthesize albumin, and were able to sustain physiological blood
pressure without harm47 .
While the primary goal for liver tissue bioengineering is to reproduce a functional
organ suitable for transplantation in recipient hosts, there is increasing interest for
using this technology for more immediate applications and particularly the
creation of an advanced disease modelling platform for preclinical drug
development and drug toxicity testing.
1.5. Current in vitro and in vivo disease modelling for chronic liver diseases
and liver cancer
The development of new drugs for the treatment of liver disease has been limited
during the last decades due to the lack of more physiological models in which
human cell biology and pathogenesis can be investigated.
1.5.1. Two-dimensional (2D) in vitro models
To date, plastic 2D monolayers are commonly used to identify molecular targets
for drug development as well as to test treatments for liver diseases48,49. Recent
advances of in vitro hepatocyte models have involved the pre-treatment of plastic
surface with ECM proteins such as collagen biomatrices, proteoglycan derivates,
soft collagen and Matrigel. However, hepatocytes cultured in this 2D-ECM coated
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systems show reduced hepatocyte-specific functions such as ammonia
metabolism, hepatic transport activity, albumin secretion and polarity50.
Because of these limitations, a novel culture system was developed in which
hepatocytes are placed between collagen type I layers (“2D sandwich”)51.
However, this system lacks of 3D organization, is degradable and characterized
by high variability52,53. Practically, the main limitation of standard 2D monolayers
is that they do not recapitulate the physiological hepatic 3D microenvironment. As
a consequence, 2D cell culture models are not reliable for providing extrapolative
data of in vivo responses54-56. In addition, drug candidates showing high efficacy
in 2D systems did not replicate their efficiency in vivo57.
1.5.2. Animal models
Animal models have been largely explored for developing drug compounds
during last three decades58. These systems overcome some of the 2D models’
limitations by providing essential physiological features such as hepatic
microenvironment, three-dimensional(3D) architecture and cellular
heterogeneity59. However, none of the existing human chronic liver diseases can
be fully reproduced in an animal model. In addition, animal models are limited in
predicting drug effectiveness because of the interspecies differences in gene and
protein expression with humans. Indeed, these differences can alter the evaluation
of drug pharmacokinetic, drug metabolism and disease adaptive mechanisms60,61.
In addition, these models are expensive, time-consuming and animal testing have
raised several ethical criticisms.
1.5.3. The need for more accurate in vitro systems
As mentioned above, in vitro and in vivo models are inefficient in recapitulating
the complexity of human physiology. This is confirmed by the high failure rate of
drug candidates in advancing through clinical trials62 mainly due to unexpected
toxicity or lack of clinical benefits in humans63.
Thus, the development of new systems for modelling human diseases is strongly
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required in order to improve the prediction of drug targets, safety and to reduce
drug development costs.
Therefore, several researchers have focused their attention on developing in vitro
3D-tissue specific platform for recapitulating the complexity of tissue
microenvironment that could be potentially scaled up to high throughput
screening (HTS) platform for evaluating new compounds/molecules and therefore
reducing animals requirement64.
1.6. 2D vs. 3D in vitro systems: the role of the microenvironment in cell
phenotype
Several studies have shown that hepatic 3D cultures show a better correlation with
the in vivo cellular response compared with 2D systems65,66. Indeed, 3D models
enable the maintenance of essential features of tissue microenvironment such as
cell-matrix and cell-cell interactions, ECM protein composition, tissue-specific
mechanical cues, topography and 3D microarchitecture. Therefore, 3D models are
considered more suitable for evaluating cell biology and investigating drug targets
than 2D culture systems.
1.6.1. Cell–cell interactions and co-culture systems
Differentiation, migration and proliferation are key cellular functions strongly
regulated by signals from other cells67.
Therefore, an ideal in vitro model needs to resemble tissue specific cell-cell
interactions to improve drug screening outcomes. 3D culture systems enable the
establishment of platform in which cell-cell interactions can be fully investigated
within 3D microenvironment68,69. The morphology and spatial organization
maintained within 3D culture systems allow for preservation of natural adhesion
between cells and this process is mainly mediated by cadherin proteins. Besides
their organizational role, cadherins transduce mechanical signals within the cells
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which in turn regulates gene expression signalling pathways70. Therefore, key
signalling pathways are maintained in 3D cultures and better resemble the in vivo
scenario when compared to 2D systems.
Furthermore, cellular heterogeneity is an essential feature of all tissues and
therefore it is crucial to recapitulate the interactions between different cell types in
order to reproduce the in vivo complexity thus enabling a full assessment of key
molecular pathways in vitro. This has been demonstrated in several studies
demonstrating a superior correlation with in vivo cellular phenotype by employing
co-culture rather than monoculture systems. For instance, 3D co-culture of hepatic
stellate cells with hepatocytes has been shown to influence several cellular
functions such as engraftment, proliferation and differentiation71-73.
1.6.2. Cell-ECM interactions
The interaction between ECM proteins and cellular receptors influence different
physiological and pathological processes74,75. This interaction leads to series of
chemical and mechanical stimuli which may affect the phenotype and function of
both ECM and cells76,77. Thus, recreating human tissue-specific ECM composition
and architecture represents an area of research actively pursued in medicine and
biology for improving the quality and validity of data generated from in vitro
cultures.
Integrins are transmembrane receptors with a key role in mediating the interaction
between cell and ECM by connecting ECM receptors with both cell membranes
and nucleus.
These proteins allow continuous regulation of cellular mechanisms in response to
environmental stimuli78 by regulating cell survival, motility, migration, invasion,
cytoskeletal arrangement and gene expression79.
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Moreover, integrins are able to sense changes in ECM biomechanical properties
(e.g. liver fibrosis and cirrhosis) during liver fibrosis and cirrhosis.
Therefore, changes in biomechanical features of tissues or materials may affect
integrin signalling pathways80. This has been showed by researchers which
highlighted significant differences in signalling pathways of cells cultured in 2D
and 3D models76,81 leading to different cell response after drug treatment.
1.6.3. Tissue architecture and oxygenation
Tissue architecture and topography has been shown to orchestrate several cellular
functions such as cell morphology, differentiation, polarization and gene
expression 82. Therefore, the development of 3D culture models needs to resemble
the complexity of spatial organization of human tissues. Indeed, the cellular
interaction with ECM proteins is mediated through the binding of both apical and
basal membrane with layers of ECM structural proteins. Unfortunately, these bi-
directional interactions are absent or disrupted in 2D models83.
In addition, oxygenation plays a key role in preserving cell function and the
process of oxygen distribution is mediated by blood vessels and capillaries in
vivo. Indeed, a key limitations of in vitro culture is the capability of generating
vascularized microtissue considering that the maximum distance between cells
and vessel is between 150 and 200 μm in vivo84. Moreover, oxygen level mediates
key cellular functions because its alteration (e.g hypoxia) affects cell proliferation
and metabolism85.
This parameter is not considered in 2D culture system because it is not possible to
recreate the oxygen gradient which characterize biological tissues86.
Therefore, the design of 3D in vitro platform requires mimicking the tissue-
specific oxygen and nutrient gradients in order to satisfy the tissue-specific
metabolic request.
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1.7. 3D in vitro hepatic systems
During last decade, advanced liver 3D models have been established for
engineering hepatic tissue by employing cell spheroids, cell sheets and scaffold-
based 3D-cultures aiming at recreating the physiological and pathological hepatic
microenvironment87. These models are summarized in the next sections
highlighting key features that require optimization.
1.7.1. Spheroids
This system allows the development of 3D hepatocyte culture by suspending
those cells in an appropriate medium and represents one of the first models
developed 88. Hepatocytes grown in 3D spheroids form multicellular clusters that
produce ECM and therefore allow cell-ECM and cell-cell interactions89,90.
Therefore, this 3D system has been proved to preserve hepatic-specific functions
and differentiation rather than 2D culture systems91. In addition, 3D spheroids
allow the study of drug pharmacokinetics and toxicity in order to identify the
most appropriate dose92.
However, the main limitation of this system is the difficulty to standardize the size
of the spheroids which is a key condition for reproducing data gathered during
drug efficacy and toxicity studies. Furthermore, the assembly of 3D spheroids
requires long time89.
1.7.2 Cell sheet stacking
The temperature-responsive culture surface can be developed by implanting a
temperature-responsive gel such as poly(N-isoproplyacrylamide) (PIPAAm), into
a standard tissue culture polystyrene dish.
This material alternates between hydrophobicity and hydrophilicity based on the
working temperatures and this further influences the capability of the cells to
attach to the material. Indeed, at low temperature (20°C) the surface of the
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material becomes hydrophilic and cells cannot attach. However, at 37°C the shell
turns hydrophobic and cells can attach and proliferate on the surface. Thus, cells
expanded on the surface can be harvested without enzymatic treatment (e.g
trypsin) but simply by reducing the temperature.
Interestingly, the interaction between cells remains preserved and several layers of
cell sheets can be assembled together in order to build more complex 3D
structures. Notably, hepatic cell sheets have been produced by employing both
parenchymal and non-parenchymal cells and this system enhanced hepatic
functions such as albumin and urea synthesis compared with 2D monolayer
cultures87,93.
Nevertheless due to absence of vascularisation and therefore of oxygen supply,
the cell sheet system can only be used for a short period of time because of the
consequent ischemic process.
1.7.3. Scaffolds/matrix-based 3D cultures
One of the most exploited systems for the development of 3D in vitro culture
platform consists in reseeding cells into 3D scaffolds. These scaffolds can be
derived from both synthetic and biological sources.
Synthetic scaffolds can be easily manufactured but lack key features such as
physiological bioactivity and biomechanics. The most common artificial matrices
employed for engineering biological tissues are synthetic polymers (e.g.
polylactide-co-glycolide (PLG), Polyethylene glycol (PEG)) and polycaprolactone
(PLA)94,95 and natural-derived hydrogels (e.g., alginates, celluloses,
polyethylene)96, respectively.
In addition, 3D scaffolds can be developed by using biological materials ECM-
construct derived. For instance, several substrates have been developed employing
basement membrane gels or type I collagen gels. These materials are
characterized by preservation of ECM molecules that improve cell attachment and
differentiation. However, several limitations characterize these biological gels.
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Firstly, it is difficult to come across batches of gel characterized by homogenous
mechanical properties97,98. Secondly, these gels do not resemble natural 3D tissue-
microarchitecture and therefore cells encapsulated in the gel randomly self-
organise in a non-physiological 3D structure. Lastly, these materials are often
non-tissue specific thus affecting the reproduction and maintenance of organ
specific metabolic function in case of liver tissue engineering99.
Figure 1.2. Tissue Engineering & Regenerative Medicine combines expertise on the fields
of cell biology, material science and tissue engineering aiming to ultimately repair and
reproduce defective or missing organs in the body.
1.8. Decellularised 3D scaffolds
As mentioned, the development of biomaterials for functional tissue engineering
requires the mimicking tissue-specific ECM and this is possible by employing
acellular tissues derived from the decellularisation of tissues and organs. This
process involves the complete removal of cellular material from the tissue while
maintaining ECM protein composition, topography and mechanical properties of
the native tissue 100.
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Figure 1.3 Schematic view of the process for obtaining human liver cubes from whole
human liver
However, decellularisation protocols needs to be tissue-specific due to the high
variability of protein compositions between different types of tissue. This section
will review reagents and techniques employed for tissue and organ
decellularisation, while highlighting those with more relevance for healthy and
diseased liver tissue.
1.8.1 Temperature
The freeze-thaw process effectively causes cell lysis within tissues and organs, but
the resulting membranous and intracellular contents remain associated with the
3D scaffold unless removed by successive processing steps.
The protocol is usually characterized by freezing the tissue at – 80°C and then
thawing the tissue at 4-37 °C. This method has been demonstrated to be effective
for lysing cells in several tissues, including adipose tissue101, lung102,
tendons103,104, ligaments105 and nerve106. However, the ECM ultrastructure may be
severely damaged by the ice-crystals formed during the freeze-thaw process107,108.
1.8.2 Hypotonic and Hypertonic Solutions
Hypotonic and hypertonic solutions are primarily used to cause an osmotic shock
to the cells without affecting ECM structure and composition. To this aim,
perfusion with hypotonic and hypertonic solutions is commonly repeated in series
to maximize the osmotic effect109-111. In addition, these solutions contribute to
wash out cell debris after cell lysis.
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1.8.3 Chemical Agents
1.8.3.i Acids and Bases
Acids and bases have a direct effect on protein structure because they modify
proteins oxidation state. Their mechanisms of actions lead to alteration of protein
folding and therefore this could facilitate the removal of cellular materials during
the decellularisation procedure.
This has been proved by De Fillipo et al. showing that ammonium hydroxide
during the decellularisation protocol contributed to the wash out of cellular
debris112. Several acids including peracetic acid113, hydrochloric acid114, acetic
acid115 and sulphuric acid116 have also been employed in decellularization
protocols leading to an improvement of the decellularisation efficiency. However,
many of these acids tend to compromise the quality of the biological scaffolds due
to the removal of key molecules such as glycosaminoglycans (GAGs) from the
ECM structure97. On the other hand, bases are not commonly employed as
decellularisation additives. Indeed, bases lead to reduction of the mechanical
properties of the tissue mainly due to the cleavage of collagen fibrils117.
1.8.3ii Non-ionic and Ionic Detergent
The mechanism of action of non-ionic detergents is mediated by the cleavage of
lipid-lipid and lipid-protein interactions without interfering with interactions
between proteins118. The most common non-ionic detergent employed in work so
far published is Triton X-100; however its effect on cell removal is still unclear.
Indeed, Dahl et al. demonstrated that Triton X-100 was not effective at
eliminating cellular or nuclear debris from vessels109, whereas Grauss et al. found
that Triton X-100 was efficient at removing nuclear material from aortic valves,
but ineffective at removing cellular debris119. In contrast with these observations,
Triton X-100 was shown to be able to effectively decellularise mice livers120.
Therefore, it is likely that these differences are strictly connected with the type of
tissue to be processed thus highlighting the importance of selecting the
appropriate cocktail of decellularization reagents to achieve full decellularization.
Interestingly, Triton X-100 preserves the integrity of collagens but influences the
composition of GAGs.
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On the other hand, ionic detergents are effective in removing cellular debris as
well as ECM proteins by modifying the interactions between proteins. The two
most common ionic detergents employed in the decellularization protocols are
Sodium dodecyl sulfate (SDS) and Sodium deoxycholate (SDC). In several tissues
tested, SDS removes most of the cellular components and disrupts the nuclear
membrane while a small percentage of nuclear materials is left in the tissue110,121-
126. Unfortunately, this treatment appears to alter the integrity of collagens110,121-126
while its impact on GAGs distribution is less evident than that reported with the
Triton X-100 treatment127. Interestingly, due to the fact the SDS is not easily
washed out from the tissue, this ionic detergent is often followed by Triton X-100
128.
SDC is a milder ionic detergent compared to SDS and it also removes cellular
components and nuclear membranes110,121-126. SDC is generally followed by step
employing nucleases in order to improve DNA/RNA extraction 129
1.8.3.iii Other reagents
Other reagents employed for decellularisation includes zwitterions and chelating
agents. These reagents are frequently used together with ionic or non-ionic
detergents. Zwitterions are characterised by both ionic and non-ionic features. For
instance, the 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS) is a zwitterion employed in decellularisation procedures. CHAPS and
zwitterions can affect the composition of ECM proteins as proved by Petersen et
al. which showed that the amount of elastin and GAGs was significantly reduced
after decellularisation with high concentration of CHAPS130.
EDTA is a chelating reagent which binds to metal ions131 and thus contributes to
cell detachment from the ECM. Its mechanism of action is mediated by the
inhibition of calcium and magnesium ions needed for cell attachment132.
1.8.4 Enzymatic reagents
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Different types of enzymes can be employed as part of decellularisation protocols
due to their capability of either disrupting interaction between cell and ECM
proteins (e.g trypsin) or removing nucleic acids (e.g nucleases).
Trypsin has been commonly used for detaching adherent cells in 2D monolayer
culture. Therefore, this enzyme in association with EDTA has been employed in
several decellularisation protocols.
However, trypsin has severe effects on the amount of ECM proteins preserved,
leading to the reduction in the amount of elastin, fibronectin, laminin and
GAGs133-135. In contrast with this, nucleases have little or no effect on the ECM
and are often combined with chemical agents in order to maximise cell material
removal. However, nucleases are not easily removed from the tissue and therefore
the processed tissue may elicit immunological responses after transplantation.
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Method Mode of action Effects on ECM Ref.
Physical forces
Snap freezing
Intracellular ice crystals disrupt
cell membrane
ECM can be disrupted or
fractured during rapid freezing
101-
108,13
6
Direct mechanical
agitation
Can cause cell lysis, but more
commonly used to facilitate
chemical exposure and cellular
material removal
Aggressive agitation can disrupt
ECM as the cellular material is
removed
109,13
3,137-
142
Sonication
Can cause cell lysis by
disrupting cel membrane
Aggressive sanitation can disrupt
ECM as the cellular material is
removed
143-
149
Chemical Agents
Acids and Bases
Solubilises cytoplasmic
components of cells, disrupts
nucleic acids, tend to denature
proteins
May damage collagen, GAG, and
growth factors
112-
115
116,11
7,150
Hypotonic and
Hypertonic solutions
Cell lysis by osmotic shock,
disrupt DNA-protein
interactions
Effectively lyses cells, but does
not effectively remove cellular
residues
109-
111,13
8
Non-Ionic detergents
Triton X-100
Disrupts lipid–lipid and lipid–
protein interactions, while
leaving protein–protein
interactions intact
Mixed results; efficiency
dependent on tissue, removes
GAGs
109,11
8-120
Ionic detergent
Sodium dodecyl
sulphate (SDS)
Solubilises cytoplasmic cells
and nuclear cellular membrane
tends to denature proteins
Removes nuclear remnants and
cytoplasmic proteins; tends to
disrupt native tissue structure,
remove GAGs and damage
collagen
110,12
1-126
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Sodium deoxycholate
(SDC)
Very similar mechanism to SDS
Mixed results with efficacy
dependent on tissue thickness,
some disruption of ultrastructure
and removal of GAG
110,12
1-
126,12
9,131
Zwitterionic detergents
CHAPS
Exhibit properties of non-ionic
and ionic detergents
Efficient cell removal with ECM
disruption similar to that of Triton
X-100
130
EDTA
Chelating agents that bind
divalent metallic ions, thereby
disrupting cell adhesion to
ECM
No isolated exposure, typically
used with enzymatic methods
(e.g., trypsin)
131-
135
Enzymes
Nucleases
Catalyze the hydrolysis of
ribonucleotide and
deoxyribonucleotide chains
Difficult to remove from the
tissue, could invoke an immune
response
110,13
0,140,1
51,152
Trypsin
Difficult to remove from the
tissue, could invoke an immune
response
Prolonged exposure can disrupt
ECM ultrastructure, removes
ECM constituents such as
collagen, laminin, fibronectin,
elastin, and GAG, slower removal
of GAG compared to detergents
133-
135
Table 1.1. Decellularisation methods: mode of action and effect on the ECM. Adapted
from Crapo et al. 2011 and Gilbert et al. 2006 131,151.
1.8.5 Techniques to apply decellularisation agents
1.8.5.i Immersion and agitation
The decellularisation of small-scale non-perfusable tissue can be achieved by
immersion in decellularisation agents while being subjected to agitation. There are
two types of mechanical agitation: indirect and direct.
Sonication is a type of indirect mechanical agitation, in which cell damage is
caused by sound waves143,144,148,149. However, complete tissue decellularisation
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cannot be achieved by employing only the sonication step144,145 but it needs to be
followed by treatments with chemical reagents146,147.
The direct agitation of tissues immersed in decellularisation agents is achieved by
employing an orbital shaker. This procedure was pioneered by Meezan and
colleagues in 1975153, who proposed this methodology for studying the basement
membrane microstructure. Subsequently, this methodology has been adapted to
decellularise sections of different tissues, including xenogenic liver, by incubating
the native tissue with different detergents but the mechanical forces employed
(expressed as g-force) have never been precisely defined 109,124,133,137,138,140-142.
1.8.5.ii Whole organ perfusion
The development of biological scaffolds with preserved vascular structure is
essential for generating 3D structures suitable for tissue engineering directed at
organ transplantation. Therefore, decellularisation reagents have been employed
for both antegrade and retrograde perfusion through the main vessels in order to
effectively reach the cells and washing out cellular materials. This technique has
allowed the development of biological scaffolds with preservation of three-
dimensional architecture and vasculature preservation.
The heart has been the first whole organ to be successfully decellularised by
retrograde coronary perfusion by Ott and colleagues in 2008. Their pioneering
protocol enabled the development of rodent heart ECM scaffold characterised by
macroscopic translucent colour and preserved vasculature structure. In addition,
they reseeded this scaffold with cardiomyocytes that formed areas with contractile
capabilities154.
Afterwards, several protocols have been employed in order to develop human and
non-human whole organs such as lung130, kidney155 and liver45,156.
Together, these studies showed the initial strategies to develop whole organ ECM
scaffold which supported cell engraftment and maintenance of tissue-specific
function.
Figure 1.4. This figure shows two approaches for developing liver biological scaffolds:
(A) Perfusion-decellularisation, which requires the perfusion of decelularisation reagents
through the main hepatic vasculature (e.g vein cava). After the development of whole
organ scaffold, these tissues can be dissected into cubes followed by static reseeding (B)
or recellularised by whole organ perfusion. (C) Agitation-decellularisation requires the
dissection of native livers into cubes followed by immersion in decellularisation reagents
and agitation. The decellularisation is a multi-step process allowing the removal of cellular
materials, proteins and DNA leading to the development of acellular translucent scaffold
(D).39
40
1.9 Aims
As already introduced, the first whole rodent liver scaffold was established in
2011 and only in 2014 a porcine human-size liver scaffold was developed.
Although biological scaffolds are characterised by lack of immunogenicity, it is
relevant to develop human scaffolds because the 3D microstructure of human
liver differs from other mammals and it would be therefore easier to translate into
clinical applications in humans. Thus, developing human acellular tissue may
have a dramatic impact towards the development of engineered tissue for
regenerative medicine and in vitro disease modelling. In addition, the
development of diseased scaffold may contribute to further understand
pathological processes in which ECM proteins play a key role in disease initiation
and progression (e.g amyloidosis).
Therefore, the work described in the present thesis has been aimed: (i) to develop
an effective protocol for the decellularisation of whole human livers and to
characterise the composition, bioactivity and biocompatibility of the resultant
hepatic ECM scaffold, (ii) to decellularise both healthy and amyloidotic mice
livers in which the key physiological and pathological features are preserved and
to assess the feasibility of perfusing the 3D mouse biological scaffold with human
amyloidogenic proteins. Lastly (iii), to develop a rapid and robust protocol in
order to produce acellular human liver cubes starting from non-perfusable tissue
and to characterise the ECM protein composition, architecture, topography and
bioactivity of the resultant scaffold.
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Chapter 2: Decellularised human liver as a natural 3D-scaffold
for liver bioengineering and transplantation
2.1 Introduction
This chapter describes the development and characterisation of healthy whole
human liver acellular scaffolds. Some of the data reported in this chapter have
been incorporated into a patent (UK patent application nº1409858.6 filed with
UCL Business) and have been recently published: Mazza, G. et al. Decellularized
human liver as a natural 3D-scaffold for liver bioengineering and
transplantation156.
The relevant figures are published under a Creative Commons Attribution CC-BY
4.0 Licence.
The area of liver tissue engineering and regenerative medicine has been
intensively explored during the last decade due to the severe shortage of organs
associated with a worldwide increase of deaths due to acute and chronic liver
diseases. Indeed, according to the World Health Organisation, the total deaths
caused by cirrhosis and liver cancer have increased by 50 million/year since
1990157. In the UK, the number of deaths from cirrhosis in those <65 years have
increased six times in the last three decades158.
Liver transplantation is the only effective treatment for patients with end stage
liver disease but unfortunately is limited by both high cost and severe shortage of
organs159. Therefore, several strategies have been developed in order to expand
the availability of livers for transplantation such us split liver transplants, living-
related partial donor procedures160 and the increasing use of “marginal” organs
such as older donors, steatotic livers, non-heart-beating donors, donors with viral
hepatitis, and donors with non-metastatic malignancy161. Despite these surgical
advancements, it is unlikely that the availability of good liver grafts will ever be
sufficient to meet the increasing demand of patients with end stage liver disease.
Therefore, more innovative approaches have been investigated including liver
support systems, such as bioartificial livers and hepatocyte transplantation.
However, their use in the clinical setting is still at an experimental level and the
relative efficacy has still to be proved162-167.
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Thus, there is urgent need of developing novel strategies in order to face the
organ-shortage crisis. The most promising approach includes the de-novo
development of functional hepatic tissue that may be used for transplantation.
Engineering a functional hepatic tissue requires the combination of both cells (e.g
stem cells or differentiated cells) and 3D-scaffolds. Although, several
advancements have been achieved with regards to cell isolation, expansion and
manipulation, the main limitation in this field is the development of scaffolds that
mimic the complexity of the human ECM network. Indeed, a number of
techniques have been employed to develop 3D scaffolds such as
electrospinning168, 3D bio-printing169 and decellularisation170. To date,
decellularised tissues and organs are the only scaffolds that resemble ECM
composition, architecture, topography and biomechanical properties of biological
tissue and therefore seem to be the most suited for liver tissue engineering.
The decellularisation of whole organs was firstly introduced by Ott et al. in 2008
with the aim to develop acellular heart from mice. This pioneering work entailed
the removal of cellular material while preserving the vascular network, ECM
composition and 3D architecture of native tissue. The preservation of those
physiological features allowed the functional engraftment of cardiomyocytes with
restoration of contractility. The perfusion protocol employed by Ott and
colleagues was characterised by retrograde coronary perfusion at constant
pressure. Afterwards, Uygun et al. adapted this protocol in order to develop the
first whole organ rodent liver scaffold. In this case, investigators used an
antegrade perfusion through the portal vein, at constant flow rate, and were able to
obtain a translucent acellular tissue within few days. Subsequently, several
protocols have been developed in order to obtain non-human liver scaffolds120,171-
173. The resulting 3D ECM scaffolds have been shown to provide an excellent
environment for the in vitro growth of multiple liver cell types retaining excellent
functionality174,175. Notably, in 2010, the repopulation of an acellular rat liver
scaffold with 50 million mature rat hepatocytes was achieved by cell perfusion via
the portal vein. Importantly, hepatocytes migrated beyond the matrix barrier to
reach the decellularised sinusoidal spaces45. In 2012, a further step onward was
43
made with the repopulation of a pig liver scaffold with human foetal hepatocytes
and stem cells176.
The main advancement achieved in the development of liver biological scaffolds
has been to scale up the decellularisation protocol for obtaining large animal
acellular livers. This is a key condition in order to develop sufficient hepatic mass
for restoring liver function upon transplantation in large animals including
humans. To achieve this result, several factors were modified including time of
organ perfusion with decellularisation reagents and most importantly flow rate
and pressure.
However, the decellularisation and repopulation of a human liver ECM scaffold
with human derived liver cells has not been so far reported by other researchers.
Notably, the human hepatic ECM displays remarkable differences in terms of
protein composition and architecture when compared with non-human livers (e.g
porcine) and therefore the ideal condition of human hepatic engineering will be to
engraft human cells within human hepatic scaffolds.
Therefore, the next section of this chapter will describe the development and
characterisation of whole human liver acellular scaffolds as well as the relative in
vitro and in vivo biocompatibility (Figure 2.1).
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Figure 2.1. Schematic study plan. Human liver unsuitable for transplantation is surgically
processed in order to obtain an isolated left lobe or is used as a whole (a-b). Lobes, or
whole organs, are cannulated and decellularised by retrograde perfusion (c). Once
decellularisation is complete, human liver scaffolds are dissected by scalpel cleavage to
obtain liver cubes (d) as a 3D-platform for biocompatibility and bioengineering studies
(e,f).
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2.2 Methods
2.2.1 Source of human livers
The work described in this thesis was performed on healthy human livers that
were harvested for transplantation and then judged unsuitable due to prolonged
graft cold ischaemic time, the presence of extra-hepatic malignancy or other
important extra-hepatic co-morbidities in donors or recipients. Livers included in
this chapter were defined “healthy” because of the absence of any degree of tissue
fibrosis and fat accumulation by histological analysis. The study was approved by
the UCL Royal Free Biobank Ethical Review Committee (NRES Rec Reference:
11/WA/0077). Informed consent for research was confirmed via the NHSBT ODT
organ retrieval pathway, and the project was also approved by the NHSBT
Research Governance Committee. Donor livers were processed in accordance
with the UCL Royal Free Biobank protocols under the Research Tissue Bank
Human Tissue Act licence, prior to use in research. Human livers obtained at the
Royal Free London Foundation Trust were coordinated, received and recorded by
the UCL Tissue Access for Patient Benefit organisation (TAPb) which links
research activities between UCL Royal Free Biobank, the Royal Free Trust and
UCL. TAPb has full governance in place for this purpose which has involved
NHSBT ODT pathway, the Human Tissue Authority licencing, and the local Trust
/ UCL Research offices.
2.2.2 Preparation of human livers for the decellularisation procedure
Upon retrieval human livers were maintained in ice. Human livers (n=7) were
either surgically processed in order to obtain the liver left lobes (n=6) including
segments 1,2,3 and 4 or retained as a whole liver (n=1) with preserved vascular
access.
In the case of whole liver preparation, the donor liver was processed exactly as
for liver transplantation. Thereafter the upper caval cuff, reaching the atrial rim,
was over sewn with a running double row of 3-0 prolene suture. The water
tightness of the organ was proofed both by antegrade portal and retrograde hepatic
venous perfusion under relative high pressure as produced by a 50 ml bladder
syringe with PBS solution.
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For segmental liver preparation of left lateral liver (S1+S2+S3+S4), dissection
was started at the hilar region with inspection, preparation, division and ligation of
the hepatic artery (HA), of the portal vein (PV) and of the bile duct (BD).
Segment 4 HA is preserved if originating from the right hepatic artery, forcing the
division of the right HA distal to its bifurcation. The right hepatic vein is divided
and the middle and left hepatic veins are preserved within the left lobe to be used
for further decellularisation. The line of parenchymal division is maintained to the
left of the line of Cantlie in order to maintain the left portion of S4. The
parenchyma is divided sharply with a knife for (of?) the liver capsule and
subsequently with crush-clamp technique, performing meticulous hemo- and
bilio-stasis. The parenchymal division is carried to the end, producing a left lateral
liver extended to S4 and a right liver as non-functional unit. Finally, the upper
caval cuff, reaching the atrial rim is over sewn with a double run of 3-0 prolene
suture.
Human livers were then frozen at -80°C for at least 24h. Indeed, tissue freezing
represents the initial step leading to the destruction of the various cellular
compartments which is key for the process of decellularisation.
2.2.3 Optimization of the various decellularisation protocols of whole human
liver
The initial protocol tested was aimed at comparing the efficiency of previously
published protocols for animal liver when employed to decellularise human livers.
This protocol was characterized by the cannulation of the hepatic portal vein and
livers (n=2) were then perfused at constant flow rate (100 ml/min) as previously
described for porcine liver47. The protocol schedule was characterized by
alternating deionized water and Sodium Deoxycholate (SDC) up to 6 weeks.
Afterwards, an alternative protocol was adopted in which both hepatic portal vein
and hepatic artery were cannulated. Livers (n=2) were perfused with the same
solutions as described above up to 6 weeks by employing different flow rates for
the vein and the artery (100ml/min and 25ml/min, respectively).
Lastly, a third protocol was investigated in which retrograde perfusion (n=3) was
adopted followed by two phases of flow rate: a) a steeply increasing flow rate to
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compensate reduced resistance and b) the stabilization of the flow rate as the
decellularisation proceeds (Figure 2.2).
In order to estimate the starting flow rate, the following formula was adopted: 0.2-
0.3 ml/min/g of liver. The increasing flow rate over the time is described in Figure
2.2.
Figure 2.2. Flow rate. The graph shows the increasing flow rate over time. The
decellularisation of a human liver left lobe (blue line) was achieved in 2 weeks, while the
decellularisation of a whole human liver (red line) was completed in 6 weeks.
An example of perfusion regime adopted for the decellularisation of a liver left
lobe is shown in Table 2.1. The decellularisation of the whole liver was performed
by repeating the procedure as shown in Table 2.1 three times (the
freezing/thawing step was performed just once).
DAY -1
Thawing the liver in PBS 1x at 4ºC overnight (o.n.)
DAY 0
Left vein cava cannulation
Cleaning tubes with:
4% EtOH (15-30 min)
PBS (15 min)
Starting retrograde liver perfusion:
100 ml/min Recycle MILLIQ 2,5l (30 min)
Change solution after 10 min
Change solution after 20 min
150 ml/min Recycle MILLIQ 2,5l (90 min)
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Change solution after 30 min
Change solution after 60 min
200 ml/min 0.025% TRYPSIN/EDTA (1h)
250 ml/min 0.025% TRYPSIN/EDTA (2h)
WASH : 250 ml/min MILLIQ
Change solution after 15 min
Change solution after 15 min
Change solution after 15 min
250 ml/min 0.025% TRYPSIN/EDTA
DAY 1
WASH: 300 ml/min MILLIQ
Change solution after 5 min
Change solution after 10 min
Change solution after 15 min
Change solution after 30 min
350 ml/min 0.01% SDS (2h)
Change solution after 1h
WASH: 350 ml/min MILLIQ (15 min)
350 ml/min 0.1% SDS (4h)
After 2h WASH: 350 ml/min MILLIQ (5 min)
Change fresh 0.1% SDS for other 2 h
WASH: 375 ml/min MILLIQ (30 min)
Change solution after 5 min
Change solution after 10 min
Change solution after 10 min
Change solution after 5 min
400 ml/min 1% SDS
After 1.5h wash: 400 ml/min MILLIQ 5 min
Change fresh 1% SDS 400 ml/mi (14h o.n)
DAY 2
WASH: 425 ml/min MILLIQ (1h)
Change solution after 15 min
Change solution after 15 min
Change solution after 30 min
425 ml/min 0.025% TRYPSIN/EDTA (5h)
WASH: 450 ml/min MILLIQ (15 min)
450ml/min 1% SDS (16h o.n)
DAY 3
WASH: 475 ml/min MILLIQ (1h)
Change solution after 30 min
500 ml/min 3% TRITON X 100
After 5.5 h WASH: 500 ml/min MILLIQ (15 min)
Change fresh 3% TRITON X 100 525 ml/min (18h o.n.)
DAY 4
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WASH: 550 ml/min MILLIQ (30 min)
Change solution after 15 min
Change solution after 15 min and Increase at 575 ml/min
600 ml/min 3% TRITON X 100
After 6h increase at 650 ml/min (17.5h o.n.)
DAY 5
WASH: 675 ml/min MILLIQ (30 min)
700 ml/min 3% TRITON X 100
After 1.5h increase at 750 ml/min
After 4.5h increase at 800 ml/min (13.5h o.n.)
DAY 6
Increase at 850 ml/min
After 3h increase at 1l/min
after 4 h WASH: MILLIQ 1.2l/min (1h)
Fresh 3% TRITON X 100 1.2l/min (18h)
DAY 7
WASH: 1.3l/min MILLIQ (2h)
1.3l/min 0.02% TRYPSIN/EDTA (7h)
After 4h increase at 1.35 l/min
WASH: 1.4l/min MILLIQ (18h o.n.)
DAY 8
Fresh MILLIQ 1.5l/min (3.5h)
After 1.5h increase at 1.55l/min
1.7l/min 1% SDS (16.5h o.n.)
DAY 9
WASH: 1.75l/min MILLIQ (3h.)
Change solution after 1h & increase at 1.755
Change solution after 1h
1.85l/min 1% SDS (4h)
After 2.5h increase at 1.9l/min
WASH: 1.7l/min MILLIQ (1.5h)
1.75l/min 1% SDS (15.5h o.n. 355 ml/min pump)
DAY 10
WASH: 1.75l/min MILLIQ (1.5h)
1.8l/min 1% SDS (5h)
WASH: 1.8l/min MILLIQ (1.5h)
1.8l/min 1% SDS (15h o.n.)
DAY 11
WASH: 1.8l/min MILLIQ (1h)
Change solution after 5 min
Change solution after 15 min
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Change solution after 30 min
1.75l/min 1% SDS (6.5h)
WASH: 1.75l/min MILLIQ (30 min)
Change solution after 5 min
Change solution after 5 min
Change solution after 5 min
Change solution after 15 min
1.75l/min 1% SDS (15h,45min o.n.)
DAY 12
WASH: 1.75l/min MILLIQ (75 min)
Change solution after 5 min
Change solution after 10 min
Change solution after 60 min
1.75l/min 1% SDS (5h)
WASH: 1.75l/min MILLIQ (1h)
Change solution after 10 min
Change solution after 50 min
1.75l/min 1% SDS (17h o.n.)
DAY 13
WASH: 1.75l/min MILLIQ (30 min.)
Change solution after 5 min
Change solution after 10 min
Change solution after 15 min
1.75l/min PBS/AA 5% (1h)
1.75l/min TX100 3% (22h,15min o. n.)
Change solution after 1h
Change solution after 6h
DAY 14
WASH: 1.75l/min MILLIQ (1.5h)
Change solution after 5 min
Change solution after 10 min
Change solution after 30 min
Change solution after 30 min
Change solution after 15 min
1.75l/min PBS (1h)
1.75l/min PBS/AA 5% (2h)
WASH: 1.75l/min MILLIQ (1.15h)
Whole organ sterilization:
1.75l/min 0.1%PAA + 4% ETOH (1h)
1.75l/min PBS (1h)
Table 2.1. Perfusion protocol. The table shows the different step employed for the
decellularisation of human liver left lobe. The decellularisation of the whole human liver
was achieved by repeating three times the procedure whown in the table.
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After decellularisation, the acellular tissue was dissected in order to assess the
homogeneity of the procedure by removing all the segments as well as all vessels
and pedicles. In addition, 125mm3 scaffold fragments (5mmx5mmx5mm) were
dissected by scalpel cleavage for liver bioengineering in vitro and in vivo
transplantation in mice.
2.2.4 Histology and immunostaining analysis
Samples were fixed for at least 24 hours in 10% neutral buffered formalin solution
(pH 7.4) at RT. Tissue was embedded in paraffin and sectioned at 4 μm. Prior to 
staining, sections were dewaxed in xylene and rehydrated using graded industrial
denatured alcohol (IDA).
Histochemical stainings: tissue sections were stained with Harris’s Haematoxylin
and Eosin (H&E) (Leica, Germany), Picro-Sirius Red (SR) (Hopkin & Williams)
(BDH Chemicals Ltd, Cellpath Ltd) and Miller’s Elastic staining with a Picro-
Sirius red counter stain (VWR, Leica, Raymond A Lamb).
Immunocytochemistry: sections stained with Collagen I, III, IV, fibronectin and
laminin were incubated in 0.5% Trypsin (MP Biomedical) / 0.5% Chymotrypsin
(Sigma) / 1% Calcium Chloride (BDH) in Tris buffered saline pH 7.6 (TBS) for
30 minutes at 37 °C. Sections stained with alpha-smooth muscle actin (α-SMA) 
were microwaved (640W) for 20 minutes in 1L of Tris-EDTA buffer (10mM Tris-
base/1mM EDTA solution, pH9.0) and sections for CD3 were pressure cooked for
3 minutes in sodium citrate buffer (10mM Sodium Citrate, pH 6.0). Slides were
then soaked in TBS with 0.04% Tween-20 (Sigma) for 5 minutes, blocked in
peroxidase blocking solution (Novocastra) for 5 minutes, washed in TBS for 5
minutes and then incubated for 1 hour in the following primary antibodies;
collagen I (Rabbit pAb to coll1 (ab34710), diluted 1:200; Abcam), collagen III
(Rabbit pAB to coll3 (ab7778), diluted 1:500; Abcam), collagen IV (mouse mAb
to coll4 (M0785), diluted 1:25; Dako), fibronectin (mouse mAb to fibronectin
(MAB1937), diluted 1:100; Millipore), laminin (mouse mAb to laminin α5-chain 
(MAB1924), diluted 1:200; Millipore), alpha-Smooth Muscle Actin (mouse mAb
to SMA, (M0851/1A4), diluted 1:500; Dako) and CD3 (rabbit pAb to CD3,
(AO452), diluted 1:200; Dako). The slides were then placed for 25 minutes in
NovolinkTM post primary (Novocastra), 25 minutes in NovolinkTM polymer
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solution (Novocastra) and developed with NovolinkTM 3,3’ di-amino-benzidine
(Novocastra) with a 5 minute wash in TBS with 0.04% Tween-20 between each
step. Slides were counterstained with Mayer’s Haematoxylin (Sigma) for 3
minutes. All sections were dehydrated in graded IDA, cleared in xylene and were
mounted with DPX (Leica biosystems); cover slipped and observed using a Zeiss
Axioskop 40. Images were captured with an Axiocam IcC5 using Zeiss
Axiovision (verison 4.8.2). All images were analysed and enhanced using Fiji
v1.49d (ImageJ Jenkins server).
2.2.5 DNA quantification
To assess total DNA content within native tissue and acellular matrices, the
DNeasy Blood and Tissue kit was used according to the manufacturer’s manual
(Qiagen). Briefly, specimens were digested with Proteinase K overnight. DNA
samples were purified using buffers provided by the company and measured
spectrophotometrically (Nanodrop, Thermo Scientific, US). Optical densities at
260 nm and 280 nm were used to estimate the purity and yield of nucleic acids.
2.2.6 Collagen quantification
The collagen content of native tissue and decellularised tissue was quantified
using the total collagen assay kit according to the manufacturer’s manual
(QuickZyme Biosciences, The Netherlands). Briefly, samples were hydrolysed in
6M HCl at 95°C for 20 hours, the hydrolysates were mixed with a chromogen
solution staining the hydroxyproline residues and color was developed at 60°C for
1 hour. The absorbance for each sample was determined at 555 nm using a
FLUOstar Omega microplate reader (BMG labtech, Germany) and the collagen
quantity was calculated by usage of a standard curve of pure collagen
hydrolysates.
2.2.7 Elastin quantification
The elastin content of native and decellularised tissue was quantified using the
FASTIN elastin assay (Biocolor, UK) according to the manufacturer’s
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instructions. Briefly, the samples were homogenized, and elastin was solubilised
in 0.25 M oxalic acid. Two consecutive incubations were performed at 95°C to
ensure complete extraction of elastin. Extracts were incubated with 5,10,15,20-
tetraphenyl-21H,23H-porphine tetrasulfonate (TPPS) dye, and absorbance was
determined at 513 nm spectrophotometrically FLUOstar Omega microplate reader
(BMG labtech, Germany). Elastin concentrations from a standard curve were used
to calculate the elastin content of the tissue.
2.2.8 Scanning Electron Microscopy (SEM)
Samples were fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer and left for
24 hours at 4°C. Following washing with 0.1 M phosphate buffer, samples were
cut into segments of approximately 1 cm length and cryoprotected in 25%
sucrose, 10% glycerol in 0.05 M PBS (pH 7.4) for 2 hours, then fast frozen in
Nitrogen slush and fractured at approximately -160°C. Next, samples were placed
back into the cryoprotectant at room temperature and allowed to thaw. After
washing in 0.1 M phosphate buffer (pH 7.4), the material was fixed in 1% OsO4 /
0.1 M phosphate buffer (pH 7.3) at 3°C for 1½ hours and washed again in 0.1 M
phosphate buffer (pH 7.4). After rinsing with dH2O, specimens were dehydrated
in a graded ethanol-water series to 100% ethanol, critical point dried using CO2
and finally mounted on aluminum stubs using sticky carbon taps. The fractured
material was mounted to present fractured surfaces across the parenchyma to the
beam and coated with a thin layer of Au/Pd (approximately 2nm thick) using a
Gatan ion beam coater. Images were recorded with a 7401 FEG scanning electron
microscope (Jeol, USA)
2.2.9 Xenotransplantation in immunocompetent mice
All animal experiments were approved by the Home Office under the UK
Animals and Scientific Procedures Act 1986 and in accordance with the
guidelines of the Comparative Biology Unit, Biological Services University
College London (UCL) under Project license 70/7100.
For biocompatibility studies, twelve male C57BL/6J mice, aged 3-4 weeks, were
used. Human liver acellular scaffolds were surgically implanted either
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subcutaneously (n=6) or into the omentum (n=6). Briefly, following shaving the
operating area, the skin was cleaned with 10% povidone iodine (Videne, Ecolab,
Leeds, UK) and 20% chlorhexidine gluconate (Hydrex pink, Ecolab, Leeds, UK).
Isoflurane (2% with 98% oxygen) was used to induce anaesthesia. For
subcutaneous implantation, a small incision (5mm) was made between the
shoulder blades and a subcutaneous tunnel was made by blunt dissection. The
human liver scaffold was inserted into the subcutaneous tunnel and the wound
was closed with absorbable 4-0 vicryl sutures. When applying an omental
implantation, a small midline abdominal incision was made and the human liver
cubic scaffold was folded within the omentum and secured in place by 6-0 vicryl
sutures. The abdomen was closed in two layers. After 7 and 21 days, mice were
euthanized and the implants along with the surrounding tissues were harvested
and fixed in 10% formalin for histological and immunohistochemical evaluation.
2.2.10 Cell Culture
The LX2 cell line is a well-established human hepatic stellate cell line that was
generated by a spontaneous immortalization in low serum conditions (kindly
provided by Professor Scott Friedman)30. Cells are cultured in Iscove’s Modified
DMEM supplemented with 2 mM/L glutamine, 0.1 mM/L non-essential amino
acids, 1.0 mM/L sodium pyruvate and 20% Foetal Bovine Serum (FBS). HepG2
and Sk-Hep-1 cells (ATCC® HTB-52™) are derived from a human
hepatoblastoma and a human hepatocellular carcinoma, respectively. Both cell
types were purchased from ATCC (VA, USA) and cultured in Eagle’s Minimum
Essential medium (EMEM), supplemented with Glutamax, 0.1 mM/L non-
essential amino acids, 1.0 mM/L sodium pyruvate and 10% FBS. All cells were
cultured under standard conditions in a humidified incubator under 5% CO2 and at
37°C. Every 3 days the complete culture medium was changed and sub-confluent
cells were trypsinized and passaged at a split ratio 1:3. For cell passaging, culture
medium was aspirated and cells were washed twice with Hank´s Balanced Salt
Solution (HBSS) and detached using 0.25% trypsin. The enzymatic activity was
stopped by adding complete culture media to the cells. Next, the cell suspension
was centrifuged at 1500 rpm for 5 minutes before calculating the cell
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concentration by using a disposable hemocytometer (C-Chip® DHC-N01, Digital
BioTM).
2.2.11 Sterilization of decellularised tissue.
As mentioned above, the whole liver was sterilized by perfusion with both PBS-
AA and PAA-EtOH (Table 2.1). The dissected cubes were further sterilized
before in vitro cell seeding by employing two different methodologies. All the
liver cubes were processed in sterile environment before proceeding with the steps
described below.
Firstly, the acellular liver tissue was immersed in PBS-AA and agitated for 45
minutes followed by a washing step in sterile PBS up to 15 minutes. Secondly, the
decellularised tissue was immersed in PAA-EtOH and agitated for 45 minutes
followed by a washing step in sterile PBS up to 15 minutes.
2.2.12 Repopulation and culture of engineered human liver
Sterilized human liver cubic scaffolds were kept overnight in complete medium
[day -1]. To start repopulation (day 0) cell cultures were trypsinized and cells
were re-suspended in a final concentration of 2 million cells per 50 µl
(2x106/50µL) per scaffold (n≥12 per cell line). Cells were drawn up in a 0.5 ml 
insulin syringe and released drop by drop to finally cover the decellularised tissue.
The tissue was turned upside down during the reseeding procedure by employing
sterile tweezers. Seeded scaffolds were kept for 2 hours in a humidified
environment at 37 °C with 5% CO2 allowing cell attachment followed by addition
of complete culture medium [day 0]. The culture medium was changed at day 1
and afterwards every 3 days. At days 7, 14 and 21 following seeding, the scaffolds
were placed in 10% formaldehyde and assessed by histology and
immunohistochemistry or fixed in 2.5% glutaraldehyde for SEM analysis.
2.2.13 Statistical analysis.
Results were expressed as mean±s.d. All data were analysed with ANOVA or
Student’s t-test. Two-tailed p values less than 0.05 were considered statistically
significant.
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2.3 Results
2.3.1 Decellularisation of human segmental lobes and whole liver
The initial two protocols employed were derived from Barakat et al and were
related to the decellularization of large scale liver47. The antegrade protocols were
ineffective in generating acellular translucent tissues. Indeed, after six weeks
perfusion the livers appeared macroscopically brownish meaning that these
protocols were unable to remove efficiently cellular materials (figure 2.3, 2.4). Of
note, the liver appeared yellowish between segments 2-3 after the perfusion period
(figure 2.3 right panel) thus indicating that the perfusion flow and the
decellularisation reagents were not homogenously distributed within the tissue by
employing portal vein perfusion.
Figure 2.3. Macroscopic appearance of human liver left lobe after 6 weeks portal vein
perfusion.
Thus, two routes of perfusion were adopted by cannulating both PV and HA.
Despite the inefficiency of this protocol to decellularise the liver left lobe at the
macroscopic level, the perfusion of the tissue seemed improved compared with
the previously described protocol because of the absence of patchy-area (figure
2.4 right panel). Moreover, the liver appeared softer by employing both protocols
thus suggesting a lack of pressure within the whole organ.
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Figure 2.4. Macroscopic appearance of human liver left lobe after 6 weeks portal vein and
hepatic artery perfusion.
Therefore, because of these two limitations observed: i) lack of pressure and ii)
lack of homogenous perfusion, a novel protocol was adopted involving retrograde
perfusion through the hepatic venous system followed by two steps perfusion rate.
In addition, the new decellularisation protocol included the usage of proteases
such us trypsine and both ionic and non-ionic detergents in order to maximize the
decellularisation efficiency.
After 2 weeks perfusion, the liver left lobes appeared macroscopically
decellularised (figure 2.5). In addition, an extended version of this protocol was
efficient in decellularising a whole human liver after 6 weeks perfusion (Figure
2.6).
Notably, during and following the decellularisation of the whole liver or left liver
lobes the tissue became gradually translucent indicating the dissolution of cells
(Figure 2.5, 2.6) with the vascular network being visualized at the macroscopic
level (figure 2.5 left panel).
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Figure 2.5. Macroscopic appearance of a decellularised left lobe showing preservation of
the vascular tree (left panel) and translucent colour (right panel).
Figure 2.6. Macroscopic appearance of a decellularised whole human liver.
2.3.2 Histological characterisation and quantitative assessment of the human
decellularised liver
After decellularisation, the one section derived from each decellularisation
procedure was dissected by scalpel cleavage and was analysed by histological
59
staining to further investigate the homogeneity of the decellularisation procedure.
Notably, Haematoxylin and Eosin (H&E) staining showed nuclei removal in all
four sections (figure 2.7). In addition, the general liver tissue architecture was
preserved as shown by Sirius red (SR) staining for collagen filaments and Van
Gieson (EVG) staining for Elastin (figure 2.7) in liver segments 1-3.
Regardless, the general architecture of segment 4 appeared to be less organized
(figure 2.7) compared to the other segments and this is probably due to the liver
split procedure performed before the decellularisation process. Thus, the future
aim is to obtain 3 decellularised segments by dissecting segment 4 after
decellularisation for future application in organ recellularisation and
transplantation.
Figure 2.7. Histological comparison of fresh liver tissue and the decellularised human
liver left lobe segments (S1, S2, S3 and S4). H&E staining showed removal of cells after
decellularisation and SR and EVG (Elastic Van Gieson) stainings show collagen (red)
and elastin (blue) preservation, respectively.
A key condition to translate the whole human liver acellular scaffold technology
for whole organ recellularisation and transplantation is the preservation of the
60
vascular tree. Therefore, the vascular (PV and HA) and biliary structure were
dissected and analysed by employing histology. As shown in figure 2.8, H&E
staining confirmed nuclei removal in all the processed vascular and biliary
structures indicating that the retrograde system was efficient in delivering the
decellularisation reagents into the portal vein, hepatic artery and bile duct.
Furthermore, SR and EVG staining showed preservation of collagen and elastin
filaments in those tissues demonstrating that although the cellular/nuclear material
was removed it was possible to preserve key structural features of the vein, artery
and bile duct.
Figure 2.8. Histological sections of the decellularised vascular (portal vein, hepatic artery
and hilar plate) and biliar tree. H&E shows absence of cells in the decellularised tissues.
SR and EVG stainings show collagen (red) and elastin (blue) preservation, respectively.
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Moreover, the removal of DNA in the ECM scaffold was confirmed by DNeasy
Blood and Tissue kit (Figure 2.9A) confirming that the total amount of DNA left
in the tissue was below 50ng/mg of tissue which is considered the acceptable
threshold for biological scaffold transplantation151. In addition, the total collagen
content was quantified and as already reported in other perfusion-decellularisation
protocols173,177,178, collagen content relative to wet weight was increased (p<0.01;
Figure 2.9B), whereas elastin was decreased (p<0.01) in the decellularised tissue
(DL) when compared with fresh liver (FL) tissue (Figure 2.9C).
Figure 2.9. Quantification of DNA and ECM proteins in both fresh liver (FL) and
decellularised liver (DL). The total amount of DNA(A) is significantly reduced after
decellularisation. The collagen content (B) increases while the elastin amount (C) is
reduced after decellularisation.
2.3.3 Immunohistochemical characterisation of the decellularised liver
After histologically confirming the preservation of collagen and elastin filaments,
a more detailed characterization of the expression and distribution of the ECM
proteins was obtained by immunohistochemistry.
This analysis showed that the expression and distribution of key ECM
components, namely collagen type I (Figure 2.10c,d), collagen type III (Figure
2.10g,h), fibronectin (Figure 2.10o,p) and collagen IV (Figure 2.10k,l) were
conserved when compared to the fresh liver. Importantly, the arrangement of each
ECM component within the acellular liver confirmed the preservation of the
architectural organisation of the original liver tissue (FL).
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Figure 2.10. Expression and distribution of ECM proteins. Collagen I, III and IV staining
in FL is seen as fine strands in the parenchymal space as well as around the blood vessels
(a,b; e,f; ij). Collagen I and III distribution was preserved following decellularisation as
demonstrated by a staining in both sinusoids and portal tracts in DL (c,d; g,h;). Collagen
IV (k,l) and fibronectin (o,p) staining showed a conserved meshwork in sinusoids and
biliary ducts after decellularisation. Scale bar for 20x magnification (left panel): 100 μm 
and 40x (right panel): 50 μm. 
2.3.4 Characterization of the hepatic micro-architecture after
decellularisation
The preservation of the ECM 3D-architecture and micro-structure is a key
condition for the development of acellular scaffolds. Thus, scanning electron
microscopy (SEM) was performed in order to evaluate the 3D hepatic micro-
architecture after decellularisation.
Initially, the overall hepatic micro-architecture was assessed at low magnification
resolution. Importantly, the portal tract and the area of the liver lobule were
preserved (figure 2.11). Next, the hepatic lobule was analysed at higher
magnification and this confirmed preservation of the hepatic honey-comb like
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structure (figure 2.12-14). Interestingly, the ECM-hepatic network was
characterised by thin layers of structural filaments with preserved organisation.
Furthermore, the hepatocyte area was assessed by scanning the tissue at higher
magnification. Notably, the hepatocyte-free space was recognised at this
magnification and it was composed by a refined network of ECM proteins
surrounding the hepatocyte pocket (figure 2.15).
Lastly, we investigated the microstructure of decellularised intra-hepatic vessels.
The intra-hepatic artery was recognised due to the muscle-like fibres with the
preservation of the inner luminal layer (figure 2.16).
Overall, these observations confirmed that the decellularisation procedure
preserved the 3D hepatic microanatomy while removing cellular materials.
Figure 2.11. Ultrastructural characaterisation of decellularised liver. Low magnification
(90x) SEM image including a portal tract surrounded by a typical lobular structure.
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Figure 2.12. Ultrastructural characaterisation of decellularised liver. SEM image (300x)
confirming scaffold acellularity and clearly defining spaces once occupied by hepatocytes
(i.e. hepatocyte-free spaces).
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Figure 2.13. Ultrastructural characaterisation of decellularised liver. SEM image (500x)
defining ECM filaments network within the liver lobule.
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Figure 2.14. Ultrastructural characaterisation of decellularised liver. SEM image (1000x)
showing different hepatocytes-free space.
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Figure 2.15. Ultrastructural characaterisation of decellularised liver. High magnification
(2500x) SEM image demonstrating a preserved three-dimensional meshwork of
connective tissue fibres structuring the hepatocyte-free spaces.
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Figure 2.16. Ultrastructural characaterisation of decellularised liver. SEM images (900x)
demonstrating preservation of an intra-hepatic artery surrounded by muscle fibres with
preserved inner luminal wall.
2.3.5 Interspecies bio-compatibility of decellularized human liver ECM
scaffolds
After confirming the acellularity of the human liver scaffold, we next assessed the
in vivo biocompatibility in a xenotransplantation model. Thus, the decellularised
human liver was dissected into 125mm3 cubes and implanted into
immunocompetent mice.
These tissues were implanted either subcutaneously (n=6) or into the omentum
(n=6), and evaluated at 7 and 21 days post-implantation.
Clinical behaviour of animals and local signs of inflammation were carefully
checked. Both subcutaneous and omental implanted acellular tissues were
assessed macroscopically, histologically and immunohistochemically for the
presence of inflammatory response, foreign body reaction and neo-angiogenesis.
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During the period of observation, mice showed normal behaviour, without local
signs of inflammation, implant exposure, extrusion or death. Macroscopic
examination at the time of enucleation showed no signs of inflammation around
the implants, such as redness and swelling, or adverse tissue reactions around the
implants, such as destruction of normal structures, at both subcutaneous and
omental sites (Figures 2.17 and 2.18, panels a,e, respectively).
Histological analysis showed absence of a foreign body reaction indicated by the
absence of giant cells or granulomata within any of the samples.
Polymorphonuclear cells and lymphocytes were observed at 7 days post-
implantation, indicating a mild inflammatory response surrounding the
implantation sites. Inflammatory cells were mostly seen in the tissue around the
implants (Figures 2.17 and 2.18, panels b,c). By contrast, at 21 days post-
implantation, reduced or no inflammatory infiltrate was observed around the
implants (Figures 2.17 and 2.18, panels f,g).
Immunohistochemistry for α-SMA revealed that alpha-SMA-negative, spindle-
like cells had infiltrated the implants after 21 days post-implantation (Figures 2.17
and 2.18, panel h). On the other hand, positivity for alpha-SMA indicated the
presence of abundant neo-vessels (mostly arterioles), initially close to the
interface host tissue/human scaffold (7 days, Figures 2.17 and 2.18, panel d) and
subsequently deeper within the scaffold (21 days, Figures 2.17 and 2.18, panel h),
thus providing evidence for neovascularisation of the implant.
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Figure 2.17. Subcutaneous implantation of liver cubic scaffolds in immunocompetent
mice. Human liver cubic scaffolds were implanted subcutaneously (n=6) and evaluated at
7 and 21 days post-implantation. Polymorphonuclear cells and lymphocytes were
observed at 7 days post-implantation, indicating a mild inflammatory response.
Inflammatory cells were mostly seen in the tissue around the implants (b,c). By contrast,
at 21 days post-implantation, little or no inflammatory infiltrate was observed around the
implants (panels f,g). Immunohistochemistry for alpha-SMA showed SMA-negative,
spindle-like cells, (most likely fibroblasts), had infiltrated the implants after 21 days post-
implantation (h) and revealed the presence of abundant neo-vessels (mostly arterioles)
initially close to the interface host tissue/human scaffold (7 days, d, arrows) and
subsequently deeper within the scaffold (21 days, h, arrows) indicating neovascularisation
of the implant. Scale bars: for 10x (b,f), 20x (c,d,g,h) magnification: 100 μm.  
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Figure 2.18. Liver cubic scaffolds implantation into the omentum of immunocompetent
mice. Human liver cubic scaffolds were implanted into the omentum (n=6), and evaluated
at 7 and 21 days post-implantation. As early as seven days after implantation, the
implanted scaffold engrafted within the surrounding host abdominal structures: recipient
liver (RL), recipient intestine (RI) and recipient pancreas (RP). Polymorphonuclear cells
and lymphocytes were observed at 7 days post-implantation, indicating a mild
inflammatory response. Inflammatory cells were mostly seen in the tissue around the
implants (b,c). By contrast, at 21 days post-implantation, little or no inflammatory
infiltrate was observed around the implants (panels f,g). Immunohistochemistry for alpha-
SMA showed SMA-negative, spindle-like cells, (most likely fibroblasts), had infiltrated
the implants after 21 days post-implantation (h) and revealed the presence of abundant
neo-vessels (mostly arterioles) initially close to the interface host tissue/human scaffold
(7 days, d, arrows) and subsequently deeper within the scaffold (21 days, h, arrows)
indicating neovascularisation of the implants. Scale bars: for 4x (b,f), 10x (c,g) and 20x
(d,h) magnification: 100 μm.  
2.3.6 Re-population of decellularized human liver ECM scaffolds with human
liver cell types
The in vitro biocompatibility was performed by reseeding the decellularised
human liver cubes with LX2 (a human hepatic stellate cell line), HepG2
(epithelial cells derived from hepatoblastoma) or Sk-Hep-1 (endothelial cells,
derived from highly invasive human adenocarcinoma) human cell types (Figure
2.19, 2.20 and 2.21).
Engineered tissues were evaluated after 7, 14 and 21 days of in vitro culture.
H&E staining showed that LX2 progressively engrafted into the acellular tissues
over 21 days (Figure 2.19 A) with a marked presence of proliferative cells (Figure
2.19 B). In addition, the number of cells increased significantly (Figure 2.19 C)
between 7, 14 and 21 days of culture (p<0.05 and p<0.001 at 14 days and 21 days,
respectively). SEM analysis (Figure 2.19 D) further confirmed that LX2 cells
migrated within the decellularised liver showing different morphologies: from a
flattened fibroblast-like cell phenotype, likely migratory, to a round-up shape
probably indicating mitosis.
Human hepatoblastoma cell lines (HepG2) successfully engrafted into the
acellular livers and migrated through the scaffold during the reseeding time
(Figure 2.20 A). Repopulation with HepG2 cells was also characterized by Ki67
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positivity indicating cells proliferation (Figure 2.20 B). Accordingly, there was a
marked increase in cell number between 7, 14 and 21 days (Figure 7h; p<0.05 and
p<0.004 at 14 days and 21 days, respectively). SEM indicated that HepG2 cells
were homogenously distributed into the decellularised liver parenchyma and
exhibited an epithelioid phenotype (Figure 2.20 D).
Metastatic Sk-Hep-1 cells were able to repopulate the liver scaffolds (Figure 2.21
A) showing a high proliferation rate (Figure 2.21 B) and the total number of cells
was remarkably increased between 7, 14 and 21 days (Figure 7l; p<0.003 and
p<0.008 at 14 and 21 days, respectively). In addition, SEM analysis showed that
these cells were able to migrate/invade within different layers of the engineered
liver scaffold showing a mesenchymal-like phenotype (Figure 2.21 D).
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Figure 2.19. Recellularization of human liver with LX2. H&E (A) and KI67 (B) showed
cell engraftment and proliferation after 21 days of bioengineering. The total cell count
increased significantly between 7 and 14-21 days(C). Scale bar 40X magnification:
50μm. SEM (D) showed that cells migrated within the decellularised sinusoidal space 
acquiring both fibroblast-like and rounded shape morphology.
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Figure 2.20. Recellularization of human liver with HepG2. H&E (A) and KI67 (B)
showed cell engraftment and proliferation after 21 days of bioengineering. The total cell
count increased significantly between 7 and 14-21 days(C). Scale bar 40X magnification:
50μm. SEM (D) showed that cells were spread through the parenchymal of the 
decellularised tissue acquiring rounded shape morphology.
77
Figure 2.21. Recellularization of human liver with SK-Hep. H&E (A) and KI67 (B)
showed cell engraftment and proliferation after 21 days of bioengineering. The total cell
count increased significantly between 7 and 14 days(C). Scale bar 40X magnification:
50μm. SEM (D) showed that cells invaded the parenchymal of the decellularised tissue 
acquiring fibroblast-like shape morphology.
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Discussion
The experiments and results presented in this chapter demonstrated the feasibility
of obtaining acellular whole human livers starting from unsuitable organs for
transplantation.
The work herein described was recently published156 and so far this is the first
report describing the decellularisation of whole human liver and human liver left
lobe.
Paul Lin et al. firstly showed decellularisation of porcine hepatic tissue in 2004.
After decellularisation, the tissue was lyophilised in order to develop ECM gel-
discs in combination with repopulating with primary rat hepatocytes.
Interestingly, these cells were characterised by a significant higher production of
albumin and urea when compared to either monolayers or collagen sandwich
cultures124.
After this pioneering work, different reports have demonstrated the successful
decellularisation of xenogenic livers including rat, rabbit or pig livers120,171-173.
However, the main challenge was to scale up the decellularisation methodology in
order to obtain human-size liver biological scaffold. Recently, Baptista et al. have
effectively decellularised porcine livers and these scaffolds were repopulated with
human foetal hepatocytes and foetal hepatic stellate cells for up to 13 days. The
engineered humanised liver showed active metabolism and albumin synthesis46.
However, the microanatomy of porcine liver is characterised by defined lobules
with connective tissue, which is absent in healthy human liver but present in
fibrotic liver179. Therefore, porcine liver scaffold may not represent the ideal ECM
for human liver tissue engineering. Indeed, it is not known whether these
differences in ultrastructure could cause complications once an engineered porcine
liver scaffold is transplanted in humans. For instance, it is possible that portal
hypertension or intravascular problems within the portal circulation would
develop if a porcine graft implant is connected with the human portal vascular
system.
Hence, due the high number of organs not suitable for transplantation as well as
key ultrastructural and architectural specific features of human liver, it would be
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ideal to improve the usage of these organs for tissue engineering and regenerative
medicine.
A major limiting factor to decellularise whole human liver as well as liver left
lobes was the inability of previously published protocols for generating human-
size liver scaffold to be effective in removing cellular materials from human
livers. Indeed, the initial designed protocol required antegrade perfusion and
constant flow rate as previously described180. However, after 6 weeks perfusion
the liver was not affected by the procedure. Afterwards, we adopted a more
complex system by perfusing the liver left lobe at constant flow rate through both
portal vein and hepatic artery. Despite this modification, the liver appeared
macroscopically brownish indicating lack of efficiency of the decellularisation
protocol. Thus, a more elaborate novel methodology was established aimed at
improving the perfusion of the whole organ by adopting retrograde perfusion as
well as a two steps perfusion rate in order to maintain the appropriate pressure
during the whole decellularisation procedure.
The retrograde perfusion concept was firstly introduced by the pioneering work of
Ott and colleagues which firstly showed the feasibility of obtaining whole organ
biological scaffold154.
The novel procedure demonstrated to be successful in removing cellular materials
while preserving the 3D-architecture and ECM protein composition. Indeed,
collagen I, IV and fibronectin were maintained after decellularisation and were
homogenously distributed within the acellular liver tissue. In addition, the
preservation of the 3D architecture was confirmed by scanning electron
microscopy where portal tract, liver lobule as well as the hepatocyte-free space
were identified.
A key feature of biological scaffold is the immunomodulatory effect upon
transplantation181. The in vivo biocompatibility was assessed in a
xenotransplantation model by implanting fragments of the acellular human liver
either subcutaneously or intra-abdominally into immunocompetent mice. Notably,
the decellularised tissues did not induce foreign body formation and the immune
response was reduced after 3 weeks of transplantation.
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Lastly, the in vitro biocompatibility was evaluated by reseeding decellularised
human liver cubic fragments with different types of human liver cell lines
including human hepatic stellate cells LX2182, hepatoblastoma cell HepG2183 and
metastatic adenocarcinoma cell SK-Hep1184.
Notably, all three cell types engrafted and migrated into the acellular liver while
maintaining the proliferative phenotype. Therefore, these experiments
demonstrated that the decellularised liver retains the key features needed to induce
homing and proliferation of human hepatic cells.
Overall the results described in this chapter offer a novel 3D biological platform
to be further developed in the area of whole organ engineering by employing
unsuitable human organs for transplantation.
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Chapter 3: Exploring the relationship between amyloidosis and
3D hepatic ECM
3.1 Introduction
This chapter addresses the development of liver biological scaffolds from both
healthy and amyloidotic transgenic mice in order to explore the intimate
interaction between amyloid deposit and hepatic-ECM. In addition, this chapter
includes the description of an ex vivo experimental model for the study of the
seeding effect of amyloidogenic proteins. This work is included in the present
thesis as an example of the application of the scaffold technology to the study of
an important human disease such as amyloidosis where the relationship between
amyloid deposits and the 3D ECM structure of the tissue is still obscure.
Some of the data included in this chapter were recently published: Mazza, G. et
al. Amyloid persistence in decellularized liver: biochemical and histopatological
characterization185.
The relevant figures are published under a Creative Commons Attribution CC-BY
4.0 Licence.
Amyloidosis is a protein misfolding disorder in which a protein or peptides lose
their solubility and self-aggregate into fibrillar polymers that precipitate in the
extracellular matrix186. The disease can be systemic when several organs are
simultaneously involved, or localized when a single organ is affected. Many cases
of systemic amyloidosis are characterized by a certain level of tissue specificity of
amyloid deposition; in these cases the amyloid deposition is prominent in a
specific organ such as the liver, the heart, the spleen or the nerves, and this
determines the specific clinical manifestations and prognosis.
Despite much progress in the study of amyloid fibrillogenesis in vitro, the
formation of amyloid fibrils in vivo is poorly understood. Comprehensive
elucidation of the processes operating under physiological and pathophysiological
conditions is now critical for understanding the natural history of amyloidosis, its
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response to available treatments and, crucially, the development of new and more
effective therapies.
Interestingly, clinical and experimental evidence suggested that some components
of the extracellular matrix (ECM), and in particular glycosaminoglycans may play
a crucial role in favouring the conversion of proteins into cross-beta fibrillar
structure and determining the tissue tropism of amyloid deposits by locally
accelerating the protein aggregation 187.
However, the precise analysis of the interaction between amyloid and the hepatic
ECM in vivo or ex vivo material has been limited by for the very high complexity
of any tissue in which cells are fully or partially conserved.
Therefore, we decided to employ the process of tissue decellularisation in
conditions suitable for the best conservation of the ECM network in order to
reduce the structural complexity of the affected organ. The feasibility of this idea
was supported by the pioneering work performed in 1986 by Bonsib and Plattner
188. Their research was aimed at improving the microscopic visualization of
amyloid and glomeruli basement membranes through the decellularisation of
small kidney biopsies. However, the decellularisation of an entire amyloidotic
organ had not previously been demonstrated. Similarly, the use of an entire liver
3D scaffold to study the deposition of amyloidotic proteins has never been
previously proposed.
As already mentioned in this thesis, successful creation of biological scaffolds for
whole organ engineering has been achieved by decellularisation of organs derived
from different tissues and species189-192. This process maintains the natural 3D
architecture, ultrastructure of the ECM as well as the patency of the vascular
network193.
The decellularisation procedure can be tailored based on the complexity of the
tissue as well as the size. Therefore, cellular materials can be removed by
employing mild procedures for small-size tissue, such us mouse liver in order to
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better preserve the biochemical composition, the bioactivity and the physical
properties of the ECM 194.
Therefore, the next section of this chapter will describe the development and
characterisation of liver biological scaffolds from healthy and transgenic
amyloidotic mice. Moreover, the application of the whole organ mouse liver
scaffold will be tested in order to investigate human protein fibrillogenesis into
3D-ECM scaffolds.
3.2 Methods
3.2.1 Transgenic mice
Amyloidosis was induced in transgenic mice, which were homozygous for both
the rTALap1 and SAA transgenes, when treated with doxycycline. Briefly, AEF
was injected into animals receiving 2 mg/ml doxycyclinein in their drinking water
for 10 days after AEF administration. This protocol consistently results in
extremely large amyloid loads 195.
3.2.2 Harvest of organs for decellularization
Mice were killed by CO2 inhalation. The abdomen was sterilized with 70%
ethanol and a U-shaped incision was performed to expose the abdominopelvic
cavity. The abdominal inferior vena cava (IVC) and portal vein (PV) were
identified and the PV was cannulated with a 24G cannula (Beckton-Dickinson),
which was secured in place with a 3-0 silk suture (Ethicon, UK). The abdominal
IVC was sectioned and 200 U of heparin injected into the portal vein. The
diaphragm was used as a holding point to release the whole liver from the
supporting tissue. The whole procedure was carried out with special caution not
to damage the Glisson’s capsule.
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3.2.3 Decellularization procedure
Mice livers were connected to a peristaltic pump (Masterflex) via the cannulated
PV and perfused with deionized water for 36 h at 4 °C. Livers were then
transferred to room temperature and were perfused with 4% (w/v) sodium
deoxycholate (SDC) (Sigma, UK) for 6 h followed by perfusion of 500 kU/ml of
DNase-I from bovine pancreas (Sigma, UK) in 1 M sodium chloride (NaCl) for
3 h. The flow rate was kept at 4.5 ml/min for the water infusion and 6.5 ml/min
for SDC and DNase steps. Following the end of the decellularization cycle
(deionised water-SDC-DNAse) the livers were perfused with PBS with 1%
antibiotic/antimycotic (Sigma, UK) for 30 minutes and stored in the same buffer
at 4 °C. The whole procedure was carried out with special caution not to remove
or damage the PV cannula.
3.2.4 Histology and Immunohistochemistry
Samples were fixed for at least 24 h in 10% neutral buffered formalin solution
(pH 7.4) at room temperature. Tissue was embedded in wax and sectioned at
4 μm.  Sections were dewaxed in xylene and rehydrated using graded industrial 
denatured alcohol (IDA) before staining with Harris’s haematoxylin and eosin
(H&E) (Leica, Germany), or Picro-Sirius Red (SR) (Hopkin & Williams) (BDH
Chemicals Ltd) or Miller’s Elastic with a SR counter stain (VWR, Leica,
Raymond A Lamb).
For AA immunohistochemistry, 2 µm sections were de-waxed, rehydrated, and
endogenous peroxidase blocked with 0.6 % hydrogen peroxidase. Sections were
then washed in PBS, and non-specific antibody binding was blocked by
incubation in 2.5 % v/v heat inactivated normal horse serum (Vector Labs,
Burlingame, CA) for 30 min at room temperature. After washing, slides were
incubated with anti-mouse SAA antibody Ab AF2948 (R&D Systems, Abingdon,
UK) diluted in Dako Antibody Diluent (1/100) overnight at 4 °C. Slides were
then incubated with IMMpress anti-goat polymer (Vector Labs, Burlingame, CA)
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for 30 min at room temperature, washed, and incubated for 10 min with
DAB/Metal (Thermo) diluted (1:10) in stable H2O2 substrate buffer. After
terminating the reaction by washing, slides were counterstained with Myers
hematoxylin for 30 s. Congo red staining was performed by the method of
Puchtler et al (1985) 196; viewing under high intensity cross polarized light
revealed the pathognomonic green birefringence of Congo red stained amyloid.
3.2.5 DNA quantification
Total DNA content within native tissue and acellular matrices was measured
using the DNeasy Blood and Tissue kit according to the manufacturer’s manual
(Qiagen). Briefly, specimens were digested with Proteinase K overnight, and
DNA was purified on a spin column; purity and yield of purified DNA were
assessed with spectrophotometric measurements at 260 and 280 nm.
3.2.6 Scanning Electron Microscopy (SEM)
Samples were fixed in 2.5% v/v glutaraldehyde in 0.1 M phosphate buffer and left
for 24 h at 4 °C. Following washing with 0.1 M phosphate buffer, samples were
cut into segments of approximately 1 cm length and cryoprotected in 25%
sucrose, 10% glycerol in 0.05 M PBS (pH 7.4) for 2 h, then fast frozen in nitrogen
slush and fractured. Samples were then placed back into the cryoprotectant at
room temperature and allowed to thaw. After washing in 0.1 M phosphate buffer
(pH 7.4), the material was fixed in 1 % OsO4/0.1 M phosphate buffer (pH 7.3) at
3°C for 1.5 h and washed again in 0.1 M phosphate buffer (pH 7.4). After rinsing
with water, specimens were dehydrated in a graded ethanol-water series to 100 %
ethanol, critical point dried using CO2 and finally mounted on aluminum stubs
using sticky carbon taps. The fractured material was mounted to present fractured
surfaces across the parenchyma to the beam and coated with a thin layer of Au/Pd
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(approximately 2 nm thick) using a Gatan ion beam coater. Images were recorded
with a 7401 FEG scanning electron microscope (Jeol, USA).
3.2.7 Protein composition of AA-mLdec and AA-mL homogenates
Crude homogenates of livers from amyloidotic SAA transgenic mice 195, i.e. AA-
mLdec or AA-mL, were prepared according to the AEF extraction procedure from
liver, through a simple homogenization of tissue in physiologic buffer (PBS)
followed by a single water extraction that provides a suspension containing
amyloid fibrils197. Total protein content in homogenates was measured using
Pierce BCA protein assay kit (Thermo Scientific) and 2 µgs of total protein were
analyzed using homogenous 15% PAGE under denaturing and reducing
conditions for further proteomics and immuno-enzymatic analyses. For proteomic
characterization, gel bands stained with colloidal Coomassie Blue were trypsin
digested before analysis of the extracted peptide mixtures by MALDI-MS
(AUTOFLEX III Smartbeam Bruker). Peptide calibration mixture (Bruker
Daltonics) in the range between 1000 and 3500 Da was used as external standard.
Immunoblot analysis following 15 % reducing SDS-PAGE was performed with
primary goat polyclonal anti-mouse SAA1 antibody (0.2 µg/ml, R&D Systems)
and secondary polyclonal anti-goat IgG peroxidase conjugate (0.65 x 10-3 µg/ml,
Dako, Denmark).
3.2.8 Amyloid enhancing factor activity in AA-mLdec
Two groups of five wild-type female C57BL/6 mice (Biological Services Unit,
UCL) aged 12-15 weeks and weighing 23 to 26 g received an injection of 0.2 ml
of AA-mLdec or AA-mL homogenates , followed by repeated subcutaneous
injections of 10% w/v casein in 0.01 M carbonate buffer. Casein was given for
5 days per week from day 1 to 14. To evaluate amyloid load, a single intravenous
tracer dose of 125I-labeled serum amyloid P component (SAP) 198 was
administered on day 23. Whole body retention of 125I was assessed after 24 and
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48h, and histological grading of Congo red stained formalin-fixed, wax-embedded
tissues was performed 199,200.
3.2.9 Amyloidogenic Protein Perfusion
Healthy decellularised mice livers were perfused with human wild type (WT) β
2m protein resuspended in PBS or with the amyloidogenic variant D76N
resuspended in PBS (0.25 mg/ml) for up to 72h at room temperature (RT). The
mice liver scaffolds were washed with PBS for 30 minutes before perfusing the
tissue withβ2m WT/D76M. To further characterize the protein structure after its
interaction with ECM proteins, the outflow solution was collected at different
time points (1h, 12h, 24h, 36h, 48h, 72h) and left at -20ºC. After 72h of
perfusion, livers were rinsed with PBS for 30 min in order to remove proteins not
specifically associated with the ECM and subsequently fixed in 10% formalin.
3.2.10 Electrophoresis under denaturing and reducing conditions
Samples were collected at 1, 12, 24, 48 and 72 hours respectively during liver
perfusion with recombinant human wild type or D76N β2-microglobulin 
(0.24 mg/ml in phosphate-buffered saline, PBS, pH 7.4) followed by extensive
rinse with PBS. 10 µl aliquots of each sample were analyzed by SDS-PAGE
under reducing conditions using gradient 8-18% Excelgel™ precast gel
(polycrylamide gel 245x110x0.5 mm, GE Healthcare).  At the same time 10μl of 
starting material and rinses at 15 and 30 min respectively were analyzed alongside
with 5μl of low molecular weight markers (GE Healthcare) containing bovine α-
lactalbumin (14.4 kDa), soybean trypsin inhibitor (20.1 kDa), bovine carbonic
anhydrase (30 kDa), chicken ovalbumin (45kDa), bovine serum albumin (66 kDa)
and rabbit phosphorylase b (97kDa). The run was carried with operating voltage
600V, current 50mA and power 30W respectively for 1.5 hour. The gel was then
stained with a solution of 0.2% Coomassie Brilliant Blue (Sigma-Aldrich) in 45%
methanol-10% acetic acid and destained with a solution of methanol-acetic acid
having the same concentration as above.
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3.2.11 Mass spectrometric analysis
Mass spectrometric analysis was carried out on a Micromass Quattro II triple
quadrupole mass spectrometer in the positive electrospray ionisation (ESI) mode.
After removal of salts using micro gel filtration columns (Bio-Gel P6-DG, Bio-
Rad) samples were vacuum dried and dissolved at a concentration of
approximately 10-50pmol/µl in acetonitrile/water/formic acid (90:10:0;1 v/v/v)
and introduced into the ion source through an infusion pump at 8µl/min. The
main operating parameters were as follows: capillary voltage 3.2 kV; cone voltage
35V; HV lens 0.5kV; Low Mass Resolution 14.6; High Mass Resolution 14.9;
scan speed 750u/s; acquisition time 1-5min. The instrument was calibrated from
700-1800 Da using horse heart myoglobin. Under these conditions proteins form
adducts with multiple protons (M+Hn)n+ and generate a series of ions related by
the function (M+nH+)/n, where M is the average molecular mass of the protein
and n is the individual ion charge. Spectra were analysed using Masslynx
software (v4) to generate a transformed spectrum showing the calculated
molecular mass of the proteins.
3.2.12 Ethical approval
The study was ethically reviewed and approved by the UCL Royal Free Campus
Ethics and Welfare Committee and the UK Home Office, and complied fully with
European Directive 86/609/EEC.
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3.3 Results
3.3.1 Perfusion-decellularization of normal and amyloidotic mice livers
The initial step was to evaluate the efficiency of mild (1 cycle) or prolonged (2
cycles) decellularisation protocols in removing cellular materials while preserving
key ECM molecules of the native tissue. The decellularization protocol was
characterised by the sequential perfusion of deionised water, sodium
deoxycholate, and DNAse through the hepatic portal vein.
As shown in figure 3.1, following the initial step of the deionised water, the livers
changed its natural red/brown colours into a paled feature and then turned
transparent after treatment with sodium deoxycholate. Notably, vessels of
different sizes were macroscopically recognised in the internal structure. After the
DNase step, the main branches from the portal vein became more visible within
the organ and all vessels became more defined, while the organ became more
transparent.
Macroscopically there were no differences observed between cycle 1 and cycle 2.
Figure 3.1. Macroscopic appearance of mouse liver during the process of
decellularisation. Following dH2O addition, the livers became blanched, with SDC
addition resulting in the livers becoming transparent. Following the DNase step, all
vessels became more defined, while the organ became more transparent.
Histological staining and DNA quantification were performed in order to assess
the efficiency of the decellularisation protocol. Cells removal was successfully
achieved in both protocols as showed by H&E staining (figure 3.2). These
findings were supported by DNA quantification (figure 3.3) showing removal of
more than 80% of native DNA.
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Figure 3.2. Histological characterisation of decellularised mouse liver tissues (1 cycle vs
2 cycles) in comparison with native tissue showing nuclei removal (H&E), collagen (SR)
and elastin (EVG) preservation at both 1 and 2 cycle of decellularisation.
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Figure 3.3. DNA quantification comparison between fresh healthy mouse liver and two
cycles of decellularisation. The figure shows significant reduction of total DNA in both
cases (<80%).
Next, the expression and distribution of proteoglycans was evaluated by Alcian
Blue staining. As shown in figure 3.4, the amount of proteoglycans appeared
reduced after 2 cycles of decellularisation. Therefore, because of the key role of
proteoglycans in establishing interaction with amyloid proteins we decided to
employ 1 cycle decellularisation protocol for further experiments.
Figure 3.4. Alcian blue comparison between fresh healthy mouse liver and two cycles of
decellularisation. The figure shows preservation of proteoglycans after 1 cycle of
decellularisation.
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After identifying the optimal protocol for developing whole liver mouse scaffold,
we tested the capability of this protocol to decellularise transgenic mice livers
overexpressing AA amyloid proteins.
As shown in figure 3.5 the macroscopic appearance after 46h perfusion (1 cycle)
showed differences between decellularized healthy livers (H-mLdec) and
decellularized amyloidotic livers (AA-mLdec). Indeed, the diseased-scaffold
retained a dense-yellowish colour although the healthy scaffold turned translucent
after the procedure.
Figure 3.5. Macroscopic appearance of healthy and amyloid mice livers before and after
decellularisation.
Thus, resultant scaffolds were characterised by histology and DNA quantification.
H&E staining confirmed nuclei removal in both tissues (figure 3.6) while few
nuclei were recognised in the diseased-scaffold. These findings were also
supported by DNA quantification showing significant reduction in the total
amount of DNA after decellularisation when scaffolds were compared with native
tissues (figure 3.7). However, there were no significant differences in DNA
content between healthy and amyloidotic decellularised livers (figure 3.8).
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Figure 3.6. H&E comparison between healthy and AA livers before and after
decellularisation. The figure shows showing nuceli removal (purple staining) after
decellularisation in both tissues.
Figure 3.7. DNA quantification comparison between healthy and AA livers before and
after decellularisation. The figure shows significant reduction in the total amount of DNA
after decellularisation.
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Figure 3.8. DNA quantification comparison between healthy and AA liver scaffolds. The
figure shows no statistical differences in total DNA content between the two
decellularised tissues.
Next, the preservation of the hepatic tissue architecture was evaluated by SR and
EVG staining. As shown in figure 3.9 collagen filaments were maintained after
decellularisation in both tissues. These filaments were mainly found into hepatic
sinusoids and microvasculature while this latter was enriched by elastin filaments
(figure 3.10).
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Figure 3.9. SR comparison between healthy and AA livers before and after
decellulariastion. The figure shows preservation of collagen filaments after
decellularisation in both healthy and amyloid tissues.
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Figure 3.10. EVG comparison between healthy and AA livers before and after
decellularisation. The figure shows preservation of elastin filaments (blue staining) after
decellularisation in both healthy and amyloid tissues.
3.3.2 Amyloid is retained in the decellularized liver scaffold
The data described so far demonstrated the feasibility of developing whole mice
liver scaffolds from both healthy and transgenic AA mice. Subsequently, sections
from native and decellularised tissues were immunostained with SAA antibodies
in order to investigate the impact of the decellularisation procedure on amyloid
deposits. As shown in figure 3.11, decellularised amyloidotic tissues (AA-mLdec)
were strongly positive when compared to sections of native amyloidotic livers
(AA-mL) indicating an overemphatization of amyloid deposits after cell
dissolution. As expected, decellularised healthy liver showed no positivity to the
staining.
In addition, the specificity of the staining was assessed by performing
immunohistochemistry without the primary antibody. As shown in figure 3.12
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there was no cross-reactivity with the secondary antibody indicating specificity of
the primary antibody to SAA.
Overall these data confirm the preservation of amyloid deposit after
decellularisation and that amyloid was diffused within the acellular tissue as well
as within the portal tracts and central veins.
Figure 3.11. Immunohistochemistry for SAA with Congo Red, and viewed under bright
field illumination (left panel) and with crossed polarised light (right panel) showing
strong positivity through the whole parenchyma in decellularised amyloidotic mice (AA-
mLdec), positivity within the portal tract of native amyloidotic mice (AA-mL) and
absence of staining in decellularised healthy mouse (H-mLdec).
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Figure 3.12. Immunohistochemistry control for all the three different conditions without
primary antibody.
3.3.3 Ultrastructural characterization of decellularized mouse liver
The pioneering work of Bonsib and Plattner indicated that the resolution of the
microscopic visualization of natural extracellular amyloid deposit can be
increased by removing cellular materials from the native tissue188 .
Therefore, scanning electron microscopy was employed to analyse the impact of
the decellularisation procedure on the hepatic ultrastructure in both healthy and
amyloidotic tissues (figure 3.13 and 3.14, respectively).
As shown in figure 3.13, there were no marked differences in terms of 3D
architecture between healthy (H-mL) and amyloidotic native tissues (AA-mL).
However, after decellularisation it was possible to appreciate key features of the
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ECM ultrastructure. Indeed, the ECM filaments surrounding the hepatocytes-free
space were highly organised in the decellularised healthy liver (figure 3.14, left
panel). In contrast, the decellularised amyloidotic liver was characterised by a
disorganised ECM network and most importantly the fibres associated to the
acellular scaffold appeared thicker and enveloped by a spongy-like structure
(figure 3.14, right panel) which was not present in the decellularised healthy liver.
Figure 3.13. SEM images of native tissues from healthy and amyloidotic tissues (left and
right panel, respectively) at two different maginification, 2000x (top panel) and 4000x
(bottom panel).
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Figure 3.14. SEM images of decellularised tissues from healthy and amyloidotic tissues
(left and right panel, respectively) at two different maginification, 2000x (top panel) and
4000x (bottom panel).
3.3.4 SAA fragments are the main components in AA-mLdec
After confirming the preservation of amyloid deposit following the
decellularisation process, we further investigated the structure and biological
function of the amyloid deposit.
In order to assess the amino acid composition of the amyloidogenic proteins,
homogenates samples from amyloidotic decellularised (AA-mLdec) and native
(AA-mL) livers were run into 15% SDS-PAGE and stained by colloidal
Coomassie blue. Interestingly, the double band corresponding to amyloid A
protein (AA) 201 was detected only in the decellularised sample (figure 3.15).
Next, the two main bands were in situ digested with trypsin and analysed by
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MALDI-MS. This evaluation confirmed that both extracted peptides contained the
1-70 amino-terminal truncated portion of murine SAA2 protein (Figure 3.16).
Lastly, homogenates from AA-mL (i) and AA-mLdec (ii) were analysed by
western blot. As shown in figure 3.17, the detection of SAA2 fragments and full-
length protein was detected in both homogenates.
Figure 3.15. SDS-PAGE of homogenates from both AA-mL (i) and AA-mL (ii) in which
a total of 2 μg of homogenates were separated in SDS 15% under reducing conditions. 1 
and 2 indicates bands subjected to mass mapping analysis.
Figure 3.16. MALDI-MS of the double bands isolated from the SDS-PAGE gel. Tryptic
peptides obtained by digestion of SDS-PAGE bands were analysed by MALDI-MS. MH+
monoisotopic values are reported for each peptide.
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3.3.5 Amyloid enhancing activity is preserved in AA-mLdec
The amyloid enhancing factor (AEF) activity is a standard in vivo analysis in
order to confirm the persistence of the supersecondary structure of amyloid fibrils
and is a prerequisite to evaluate the capacity of natural amyloid to accelerate the
fibrillar conversion of amyloidogenic protein precursors. Indeed, one injection of
AA amyloid tissue in association with repeated casein administration accelerates
amyloid deposition197,202.
Therefore, we assessed the AEF activities of both AA-mL and AA-mLdec
followed by casein administration (figure 3.18). As shown in figure 3.19, there
were no differences in 125I-labeled serum amyloid P component (125I-SAP)
retention and congo red staining of both spleen and liver (figure 3.20) 14,15.
Figure 3.17. Schematic view of the amyloid enhancing factor (AEF) procedure.
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Figure 3.18. 125I-SAP retention at 48 hours. The figure shows no differences between
native and decellularised amyloidotic livers.
Figure 3.19. Amyloid score in vivo. The figure shows no differences between native and
decellularised amyloidotic livers.
3.3.6 Interaction with liver ECM scaffold induces amyloidogenesis of D76N
Lastly, we explored the feasibility of developing a whole organ perfusion system
for evaluating the 3D interaction between amyloid proteins (wild type β2m and
pathological variant D76N) and hepatic ECM scaffold derived from healthy
mouse liver.
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The outflow collected from the perfused livers was analyzed by 15% acrylamide
SDS-PAGE in order to define the protein structure after interacting with liver
ECM scaffold. As shown in figure 3.21 the wild type β 2m protein still
maintained its globular structure after 48h perfusion. Interestingly, the
pathological variant D76N modify its globular structure generating several protein
fragments after interacting with the bioactive liver ECM scaffold. The data
generated by the 15% acrylamide SDS-PAGE were confirmed by employing ESI-
MS (figure 3.22). In fact, based on the proteomic data, the outflow collected from
the liver ECM scaffold perfused with the pathological protein variant contains a
higher number of protein fragments when compared with the wild type.
Figure 3.20. 15% SDS PAGE of perfusate from both WT and D76N. The figure indicates
the presence of protein fragments in the perfusate from D76N.
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Figure 3.21. ESI-MS of perfusate from both D76N and WT (top and bottom,
respectively) confirming the presence of protein fragmentation after perfusion with
D76N.
After 72h of protein-perfusion, the livers were rinsed in PBS to remove all the
proteins which were not stabilized to the ECM. Thus, the livers were analyzed by
immunohistochemistry for the presence of human β2m aggregates. Notably, the
liver perfused with the D76N protein variant contained protein aggregates that
were not present in the liver perfused with the wild type (figure 3.23). Therefore,
the variant protein which causes amyloidosis in vivo reveals an inherent
predisposition to aggregates after interacting with liver ECM scaffold.
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Figure 3.22. Immunohistochemistry for beta-2m of livers perfused with either WT protein
or amyloid variant D76N (top and bottom, respectively). The figure shows protein-like
aggregates in thei main vasculature structure of livers perfused with amyloid variant
D76N.
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3.4 Discussion
The results described in the first part of this chapter showed the possibility of
decellularising amyloid liver while maintaining the diseased-associated features
such amyloid deposit. Therefore, we showed that the structure and biological
function of amyloid deposit were preserved after decellularisation.
The experimental model and preliminary results reported in the last part of this
chapter emphasised the feasibility of developing a whole organ perfusion model
in which amyloid proteins can be perfused through the natural vascular system of
3D-ECM scaffolds.
Interestingly, the process of cell removal highlighted key features of the hepatic
ultrastructure that were not detected in the native tissue. This concept was firstly
introduced by Bonsib and Plattner et al. in 1986 188,203. However, their findings
revealed a globular structure covering the surface of ECM filaments suggesting
that those structures were amyloid fibrils. Our data confirm that analysis of the 3D
microstructure may be improved by removing cellular materials from the organ.
However, the resultant scaffold generated through our protocol is characterised by
spongy-like structure that affect the physiological arrangements of ECM network,
mainly composed by fine filaments.
The differences between our protocol and previously published work can be
explained by different methodologies employed for achieving tissue or organ
decellularisation. Indeed, our decellularisation protocol was characterised by
perfusion through the main vascular tree of mild decellularisation agents including
SDC194,204. Thus, we propose that our mild protocol enables the identification of
key ultrastructural features that were identified just after decellularisation of
amyloid tissue. These findings were supported by protein analysis of tissue
homogenates from both native and decellularised amyloid tissues revealing the
presence of SAA fragments. Furthermore, homogenates from amyloidotic
decellularised livers maintains their amyloid enhancing factor activity after
injection in mice. Therefore, this confirmed that the decellularisation process
preserves amyloid deposits while revealing key ultrastructural features without
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altering the functional property of natural fibrils to prime amyloid growth and
propagation.
These ultrastructural features emerging from SCAN microscopy suggest that
biomechanical properties of amyloid tissue may be altered such as organ elasticity
and fluid permeability of the extracellular space and thus explaining the increased
hepatic tissue stiffness of patients with amyloidosis205.
In addition, our mild decellularisation procedure maintained key ECM molecules
involved in amyloid fibrillogenesis such as the abundant presence of
glycosaminoglycans stained by Alcian Blue206.
For this reason, we propose that the whole organ scaffold may be employed for
the study of the interaction between amyloid and ECM proteins. Our preliminary
results showed the feasibility of perfusing whole mouse liver scaffold with human
wild type and pathogenic β2-m variant. It is worth noting that the β2-m variant 
and not the wild type after several passages into the liver scaffold revealed several
proteolytic cleavages. The early cleavage occurred in the N-terminal strand of the
protein that is known to become highly flexible in the early phases of amyloid
conversion207. Therefore the decellularized scaffold not only maintains a native
like 3D structure, but also some proteolytic enzymes are still fully active. We
hypothesize that intrinsically unstable globular amyloidogenic proteins such as
this b2-m variant (Asp76-Asn)208,209 can become partially unfolded once exposed
to the shear forces present in the perfused liver scaffold. The hydrophobic surface
of ubiquitous fibrous proteins of ECM (i.e. collagen and elastin) provides a
prominent contribution to the generation of the shear forces for the unfolding of
globular proteins207 and the proteins became highly susceptible to proteolytic
cleavage210 as well as to self aggregation. The tissue scaffolds obtained using the
methodology herein proposed can become a unique tool for recapitulating in a
biomimetic system the effect of biomechanical forces into two crucial
pathogenetic steps of amyloidogenesis of globular proteins: selective proteolytic
cleavage and self aggregation.
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Chapter 4: Three dimensional human liver acellular scaffolds
with preserved architecture and physiochemical properties for
functional tissue engineering
4.1 Introduction
This chapter addresses the development of small scale human liver biological
scaffolds in order to develop a natural material for in vitro hepatic tissue
engineering. Data reported in this chapter have been incorporated into a patent
(UK patent application nº 1513461.2 filed with UCL Business).
The development and functionalisation of biomaterials have been actively pursued
to enable more effective applications of tissue engineering. In particular, the
development of 3D-biological scaffolds, based on a natural extracellular matrix
(ECM) protein structure, has been shown to provide a more physiological
platform for cell engraftment and function45,155. Functionalised 3D biomaterials
allow the study of cell/tissue biology in the presence of biochemical and
biomechanical stimulants within the physiological spatio-temporal context174,211.
In addition, the understanding of human physiological and pathophysiological
conditions could be improved by employing appropriate 3D-ECM
microenvironments reflecting the complexity of normal and diseased tissues
185,212-215.
The main challenge in liver tissue engineering is to recapitulate the complexity of
human liver. The hepatic ECM is a complex network of macromolecules that not
only provides cells with an extracellular scaffold but also plays an important role
in the regulation of cellular functions216,217. Although biochemical signals are
fundamental in the regulation of cell behaviour, including differentiation and
motility, this is also markedly influenced by the surrounding mechanical
environment, including structural topography and tissue stiffness218-221. Therefore,
biomaterials should be able to reproduce the essential features of the physiological
extracellular scaffold including tissue-specific ECM protein composition, 3D-
microarchitecture, stiffness and pro-angiogenic properties in order to support
cellular growth and maintenance of cell phenotypes.
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As extensively detailed in the previous chapters of this thesis, decellularization is
a process that removes cellular and immunogenic materials from tissues and
organs while maintaining the mechanical and bioactive properties of the tissue222.
This allows the optimal recellularization with organ-specific cell types leading to
the development of engineered tissues and organs. Accordingly, major advances
in the decellularization-recellularization technology have been achieved for the
development of whole engineered organs due to their attractive application in the
area of whole organ transplantation45,155,223-226.
Despite the progress achieved in the development of whole organ scaffolds, no
advancement has been reported for the decellularization of tissue sections.
Importantly, the development of small scale acellular scaffolds could provide
tissue-specific 3D-ECM platforms to be used as an alternative to standard 2D-cell
cultures on artificial materials such as plastic. This will allow the introduction of
in vitro experimental conditions closer to human physiology and pathology.
The main aim addressed in this chapter was to develop a novel methodology for
improving the generation of small size 3D-ECM scaffold from sections of healthy
human liver. This methodology, based on high g-force oscillation/high flow shear
stress and markedly reduced processing time, represents an alternative to the
established agitation-decellularization procedures so far reported124,153 which are
characterized by lengthy procedures and prolonged exposure to detergents leading
to suboptimal decellularization.
Therefore, the next section of this chapter will describe the development and
characterisation of small scale liver tissue scaffolds and the tissue engineering
with different types of human hepatic cells.
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4.2 Methods
4.2.1 Source of human livers
The work described in this paper was performed on healthy human livers that
were harvested for transplantation and then judged unsuitable because of
prolonged graft cold ischaemic time, the presence of extra-hepatic malignancy or
other important extra-hepatic co-morbidities in donors or recipients. Livers
included in this study were defined “healthy” because of the absence of any
degree of tissue fibrosis and fat accumulation by histological analysis. The study
was approved by the UCL Royal Free Biobank Ethical Review Committee (NRES
Rec Reference: 11/WA/0077). Informed consent for research was confirmed via
the NHSBT ODT organ retrieval pathway, and the project was also approved by
the NHSBT Research Governance Committee. Donor livers were processed in
accordance with the UCL Royal Free Biobank protocols under the Research
Tissue Bank Human Tissue Act licence, prior to use in research. Human livers
obtained at the Royal Free London Foundation Trust were coordinated, received
and recorded by the UCL Tissue Access for Patient Benefit organisation (TAPb)
which links research activities between UCL Royal Free Biobank, the Royal Free
Trust and UCL. TAPb has full governance in place for this purpose which has
involved NHSBT ODT pathway, the Human Tissue Authority licensing, and the
local Trust / UCL Research offices.
4.2.2 Decellularization Protocols
Human livers (n=4) were perfused with PBS-1X allowing removal of blood and
were stored at -80°C for at least 24h for the purposes of initial destruction of the
various cellular compartments.
Afterwards, human livers were thawed at 4°C overnight and liver tissue cubes
(LTCs) (n>200/liver) were obtained by scalpel cleavage (125mm3) and stored at -
80°C.
Figure 4.1. Schematic view of the process for developing human liver cubic scaffolds.
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Initially liver cubes were thawed in a water bath at 37 °C for 1 hour, followed by
the addition of 1.2 ml of 1% PBS for 15 minutes. Once thawed the cubes were
transferred into 2ml safe-lock tubes (Eppendorf). A standardized 1.5 ml of each
solution is added to its respective tube and different protocols were performed.
The agitation regime for the decellularization of the LTC is shown in Table 4.1
and 4.2.
The reagent mixture was characterized by : 3%SDC, 0.5%SDS, 0.3%Triton X100,
4.3% NaCl, 0.0025% Trypsin/EDTA.
Table 4.1. Protocol description: orbital shaker (OS) and magnetic stirrer (MS).
Table 4.2. Protocol description: high g-force oscillation.
4.2.3 Histology and immunostaining analysis
Four μm sections were taken from formalin fixed paraffin embedded blocks and 
were de-waxed and rehydrated prior to staining (Xylene + IDA).
Histochemical stains: All sections were stained with Haematoxylin and Eosin
(H&E) (Leica, Germany), Picro-Sirius Red (SR) (Hopkin & Williams) (BDH
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Chemicals Ltd, Cellpath Ltd) and Miller’s Elastic stain with a Picro-Sirius red
counter stain (VWR, Leica, Raymond A Lamb).
Immunocytochemistry: sections to be stained with Collagen I, III, IV, fibronectin
and laminin were incubated in 0.5% Trypsin/0.5% Chymotrypsin/1% Calcium
Chloride (BDH) in Tris buffered saline pH 7.6 (TBS) for 30 minutes at 37 °C.
Sections stained with alpha-fetoprotein (AFP), Factor VIII, TGFβ receptorCD31 
were microwaved (640W) for 5 minutes, 10 minutes, 15 minutes and20 mins
respectively and EPCAM and PDGFβ receptor pressure cooked for 3 minutes and 
4 minutes respectively, in sodium citrate buffer (pH 6.0).
Slides were blocked in peroxidase blocking solution (Novocastra) for 5 minutes,
washed in TBS for 5 mins and then incubated for 1 hour in the following primary
antibodies; AFP (1:200; Dako, A0008), collagen I (1:200; Abcam, ab34710),
collagen III (1:500; Abcam, ab7778), collagen IV (1:25; Dako, M0785), EPCAM
(1:50; Leica Biosystems, NCL-ESA), (fibronectin (1:100; Millipore, MAB1937),
laminin (1:200; Millipore, MAB1924), and Factor VIII (1:1000; Dako, A0082),
PDGF-βR (1:50) and TGF-βR (1:50). 
Primary antibodies were detected by usage of the NovolinkTM kit (Novocastra
RE7280-K). Sections were dehydrated, cleared and mounted, and images were
captured with an Axiocam IcC5.
4.2.4 DNA quantification
To assess total DNA content within native tissue and acellular matrices, the
DNeasy Blood and Tissue kit was used according to the manufacturer’s manual
(Qiagen). Briefly, specimens were digested with Proteinase K overnight. DNA
samples were purified using buffers provided by the company and measured
spectrophotometrically (Nanodrop, Thermo Scientific, US). Optical densities at
260 nm and 280 nm were used to estimate the purity and yield of nucleic acids.
4.2.5 Collagen quantification
The collagen content of native tissue and decellularized tissue was quantified
using the total collagen assay kit according to the manufacturer’s manual
(QuickZyme Biosciences, The Netherlands). Briefly, samples were hydrolyzed in
6M HCl at 95°C for 20 hours, the hydrolysates were mixed with a chromogen
solution staining the hydroxyproline residues and color was developed at 60°C for
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1 hour. The absorbance for each sample was determined at 555 nm using a
FLUOstar Omega microplate reader (BMG labtech, Germany) and the collagen
quantity was calculated by usage of a standard curve of pure collagen
hydrolysates.
4.2.6 CAM assay
Chicken chorioallantoic membrane (CAM) angiogenic assay
CAM assay was performed to assess the angiogenic properties of the
decellularized liver in vivo177,227. Briefly, fertilized chicken eggs (Henry Stewart
and Co.) were incubated at 37°C at constant humidity. At day 3 of incubation 2 ml
of albumin were aspirated from the acute end of the egg using a 21-G gauge
needle attached to a 5 ml syringe. An oval window of approximately 3 cm in
diameter was cut into the shell to reveal the embryo and CAM vessels. The
window was sealed with Sellotape and the eggs were returned to the incubator for
a further 5 days. At day 8 of incubation, 1 mm3 ALTCs were placed on the CAM
between branches of the blood vessels. Sterile inert mesh loaded with PBS or 200
ng/mL VEGF (Sigma) was used as a negative and positive control respectively.
CAMs were examined daily until 7 days after placement of matrices, and
photographed in ovo with a stereomicroscope equipped with a Camera System
(Leica) to quantify the blood vessels surrounding the matrices. To assess
angiogenesis, the number of blood vessels converging towards decellularized
matrices was counted manually. Only blood vessels less than 10 mm in diameter
were counted by blinded assessors (n = 4), with the mean of the counts being
considered.
4.2.7 Scanning Electron Microscopy (SEM)
Samples were fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer and left for
24 hours at 4°C. Following washing with 0.1 M phosphate buffer, samples were
cut into segments of approximately 1 cm length and cryoprotected in 25%
sucrose, 10% glycerol in 0.05 M PBS (pH 7.4) for 2 hours, then fast frozen in
Nitrogen slush and fractured at approximately -160°C. Next, samples were then
placed back into the cryoprotectant at room temperature and allowed to thaw.
After washing in 0.1 M phosphate buffer (pH 7.4), the material was fixed in 1%
OsO4 / 0.1 M phosphate buffer (pH 7.3) at 3°C for 1½ hours and washed again in
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0.1 M phosphate buffer (pH 7.4). After rinsing with dH2O, specimens were
dehydrated in a graded ethanol-water series to 100% ethanol, critical point dried
using CO2 and finally mounted on aluminum stubs using sticky carbon taps. The
fractured material was mounted to present fractured surfaces across the
parenchyma to the beam and coated with a thin layer of Au/Pd (approximately
2nm thick) using a Gatan ion beam coater. Images were recorded with a 7401
FEG scanning electron microscope (Jeol, USA).
4.2.8 Second harmonic generation (SHG) microscopy and autofluorescence
imaging
Both native tissue and decellularized liver scaffolds were cryoprotected and
sections were then set in a mold and covered in OCT cold embedding media and
frozen. The OCT blocks containing the liver tissue/scaffolds were cryosectioned
to a thickness of 20 μm and mounted on glass slides. Prior to measurements 
samples were thawed for 15 min in PBS.
All SHG images were obtained using a custom built multiphoton microscope
incorporating an upright confocal microscope (SP5, Leica) and a mode-locked
Ti:Sapphire Laser (Mai Tai, Newport Spectra-Physics). Images of the SHG signal
from collagen I were collected using an 820 nm excitation with SHG signal
obtained with a 414/46 nm bandpass filter and multiphoton autofluorescence
signal obtained with a 525/40 nm bandpass filter. A 25X, 0.95 NA water-
immersion objective (Leica) was used to deliver excitation signal and to collect
the SHG emission signal from the sample. Images with a 600 μm x 600 μm field 
of view were obtained with 2048 pixel resolution and a line rate of 10Hz giving a
pixel resolution of ~0.3μm with 3X averaging on each acquisition to reduce the 
effect of noise.
4.2.9 Atomic Force Microscopy (AFM)
AFM sample preparation:
Tissue samples for AFM measurement were prepared by taking tissue slices from
a cube of liver tissue. Thick tissue slices were cut from the tissue cube using a
scalpel, under liquid conditions and were kept in PBS at room temperature prior to
attachment to a petri dish for analysis within 30 minutes. A slice of tissue
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measuring 5mm x 2mm x 2mm was attached to a petri dish using two droplets of
Cyanoacrylate adhesive, applied with a 10 μl pipette tip, placed at the extremities 
of the sample. After tissue slice attachment (1-2 min) the slice was immersed in
PBS in order for the AFM measurements to be conducted within a 2 h time
period. In the case of tissue scaffold samples, scaffold cubes were removed from
storage in PBS at 4°C and excess liquid removed with a tissue prior to attachment.
As previously described for the tissue slices, tissue scaffold cubes were attached
to petri dishes with two droplets of adhesive at the extremities. After attachment
(1-2 min) scaffolds were immersed in PBS and imaged within 2 h.
AFM Measurements:
Measurements of the tissue slices and scaffold cubes have been conducted on a
JPK Nanowizard-1 (JPK Instruments) operating in force spectroscopy mode,
mounted on an inverted optical microscope (IX-81, Olympus). AFM pyramidal
cantilevers (MLCT, Bruker) with a spring constant of 0.07 N/m were used with a
35 μm glass bead attached to cantilever tip. Prior to measurements with the 
adapted cantilevers, their sensitivity was calculated by measuring the slope of
force-distance curve in the AFM software on an empty region of the petri dish.
For indentation tests on the sample, the cantilever was aligned over regions in the
middle of the samples using the optical microscope. For each sample 30-50 force
curves were acquired in 6-10 different 100 μm regions, this arrangement allowed 
force-curves to be acquired in locations at least 50-100 μm apart. Force-curve 
acquisition was carried out with an approach speed of 5μm/s and a maximum set 
force of 1.5 nN. Elastic modules were calculated from the force-distance curves
by fitting the contact region of the approach curve with the Hertz contact model,
using the AFM software.
4.2.10 Raman Spectroscopy
Raman spectra were collected using an inverted optical microscope (Eclipse Ti,
Nikon) equipped with a 63x/ 1.2NA oil immersion objective. A 785 nm excitation
laser, with the power of 50 mW at the sample, was used for excitation. The
Raman back-scattered light was collected by the same objective and collimated
towards an optical spectrometer (RiverD International) equipped with a deep-
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depletion back-illuminated CCD (Andor Technology, UK). Raman maps were
measured by raster-scanning the A movable stage (Prior Pro-scan ii) is equipped
to allow spectral imaging. For measurements, the samples were placed on a 1 mm
thick quarz window. Raman spectral mapping were recorded for tissue areas of 4
x 4 mm2 with a step size of 20 m. The integration time at each pixel was 0.5
seconds. Auto-fluorescence images of the tissue samples were recorded for the
same areas using a confocal scanner (C2, Nikon) integrated to the Raman
microscope. The excitation was based on a laser at 405 nm (10mW) and detection
in the range 450-480 nm.
4.2.11 Proteomics
Proteomic analysis was performed on 5μm slide of tissue (native and ALTC) 
previously fixed in formalin. The slide was removed by scalpel cleavage and it
was analysed following the method of Rodriguez et al228. Following extraction
into 10mM Tris/1mM EDTA/0.002% Zwittergen buffer (99 °C, 1.5 h) and
sonication (1 h), samples were trypsinized (1.5 mg w/v) overnight at 37 °C and
then reduced with dithiothreitol (50 µg) at 99 °C for 5 minutes. Digests were run
on a nanoACQUITY™ UPLC system (Waters Ltd., Elstree, Hertfordshire, WD6
3SZ) coupled to an Orbitrap Velos Mass Spectrometer (Thermo Electron,
Bremen, Germany. MS data files were analyzed using Mascot229.
4.2.13 Cell Culture
The LX2 cell line is a well-established hepatic stellate cell line that was generated
by spontaneous immortalization in low serum conditions30. Cells are cultured in
Iscove’s Modified DMEM supplemented with 2 mM/L glutamine, 0.1 mM/L non-
essential amino acids, 1.0 mM/L sodium pyruvate and 20% Foetal Bovine Serum
(FBS). HepG2 (ATCC® HTB-52™, VA, USA) are derived from human
hepatoblastoma and were cultured in Eagle’s Minimum Essential medium
(EMEM), supplemented with Glutamax, 0.1 mM/L non-essential amino acids, 1.0
mM/L sodium pyruvate and 10% FBS. Human umbilical vein endothelial cells
(HUVEC pooled; PromoCell) were cultured in low-serum (2% V/V) ECGM with
supplemental mix (PromoCell) and used between passage 3 and 5. All cells were
cultured under standard conditions in a humidified incubator with 5% CO2 at
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37°C. Every 3 days the complete culture medium was changed and sub-confluent
cells were trypsinized and passaged at a split ratio 1:3.
4.2.14 Repopulation and culture of engineered human liver
Scaffolds were kept overnight in complete medium [day -1]. Cells were re-
suspended at a concentration of 2 million cells per 50 µl (2x106/50µL) per
scaffold (n≥12 per cell line). Cells were drawn up in a 0.5 ml insulin syringe and 
released drop by drop to finally cover the decellularized tissue. Seeded scaffolds
were kept for 2.5h in a humidified environment at 37 °C with 5% CO2 allowing
cell attachment followed by addition of complete culture medium [day 0]. The
culture medium was changed at day 1 and afterwards every 3 days. At days 7 and
14 (LX2, HepG2) and days 3 and 7 days (HUVEC) following seeding, the
scaffolds were placed in 10% formaldehyde and assessed by histology and
immunohistochemistry or fixed in 2.5% glutaraldehyde for SEM analysis. In
addition, reseeded samples (quadruplicates) were snap frozen for further gene
expression analysis.
4.2.15 RNA extraction and qRT-PCR.
Total RNA was extracted from 2D and 3D cultures using TRIzol reagent and
RNeasy Universal Mini Kit (Qiagen). One microgram of total RNA was reverse
transcribed with random primers and MultiScribe RT enzyme (Applied
Biosystems, Paisley UK).
Gene expression was measured using Taqman gene expression assays with the
Applied Biosystems® 7500 Real-Time PCR system (Supplementary Table 2).
Table 4.3. RT-PCR probes list.
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4.2.16 Statistical analyses.
Results were expressed as mean±s.d. All data was analysed with ANOVA or
Student’s t-test. Two-tailed p values less than 0.05 were considered statistically
significant. Expression levels for each gene were calculated using the delta Ct
method230 and normalized to the ones of GAPDH as reference gene. Graphs
depict averages ± SEM of the relative gene expression data (n=3 or 4/group).
Statistical analysis was performed with two-way ANOVA with Bonferroni’s
multiple comparisons test, using Prism GraphPad software.
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4.3 Results
4.3.1 Optimization of the agitation-decellularization procedure of human
acellular liver tissue cubes
The procedure was carried out by employing a stepwise protocol using increasing
g-force intensities in order to remove immunogenic cellular materials whilst
preserving ECM proteins as well as reducing the processing time and exposure to
detergents. Therefore, the first step was to define the g-force value to be employed
during agitation-decellularization and then apply this value consistently in the
different protocols.
4.3.1.1 Determining G- force
The agitation systems were characterized by different agitation speeds defined by
different g-force values. The g-force, which refers to the relative centrifuge force
(RCF), is expressed as RCF = 1.118 ∗ 105 ∗ r ∗ (rpm)ଶ and was adopted to
estimate the g-force value employed in previously published protocols using
either orbital shaker or magnetic stirrer 133,140,142.
The novel system that we planned to use for decellularizing biological tissue
considers a tissue sample undergoing harmonic motion with frequency f Hz and
amplitude Û m and assuming it starts at zero displacement (i.e x=0 and t=0) will
occupy the position ݔ= Û݅ݏ (݂݊∗ 2 ∗ ߨ ∗ ݐ) (considering the difference in density
between the tissue and it surrounding solution is negligible). Furthermore, a
particle (or tissue in this case) which moves under simple harmonic motion will
be represented by the equation ݔ’’ = −ݓ2ݔ , where ݓ = 2 ∗ ݌ ∗݅ ݂ .
Reformulating these equation according to Newton second law, Force (F) equals
mass (m) multiplied by acceleration (a) [F=ma], results in the equationܨ=
−݉ [(2 ∗ ߨ ∗ ݂ )2] ∗ Û݅ݏ (݂݊∗ 2 ∗ ߨ ∗ ݐ) . This is extremised when |sin|=1.
Therefore, it will be at its maximum/minimum when ܨ = +/−Û݉ [2 ∗ ߨ ∗ )݂2].
Finally by dividing the equation by the force experienced by gravity (mg), the
equation for g− ݋݂ܿݎ ݁= (Û/݃) ∗ [(2 ∗ ݌ ∗݅ )݂2] .
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4.3.1.2 Protocol optimization.
Healthy human LTCs were employed for optimizing the protocol of agitation
decellularization (Figure 4.2). Initial experiments illustrated in Figure 4.3 and 4.4
employed low g-force intensity (0.4g). After 8 (Figure 4.3) and 16 (Figure 4.4)
days of agitation with an orbital shaker (protocol OS1 or OS8 and OS2 or OS16),
the resultant tissue appeared macroscopically brownish indicating a non-complete
tissue decellularization. Histological examination (Hematoxylin and Eosin (H&E)
and Sirius Red (SR) revealed the presence of cellular materials within the tissue
(Figure 4.3, 4.4). Although, DNA quantification showed a significant reduction in
the total amount of DNA after the procedure (p<0.001; Figure 4.6) this was still
above the standard threshold of 50ng/mg of tissue222 .
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Figure 4.2. Histological characterization of native liver cubes. Macroscopic appearance of
native liver (A) and histological characterization confirming absence of both fat
deposition (B,C) and fibrosis (D-G). Scale bar B,D,F=200 μm and C,E,G = 50 μm. 
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Figure 4.3. Histological characterization of orbital shaker protocol-1. Schematic view of
the sample movement (A). Macroscopic appearance and histological analysis after
decellularisation using an orbital shaker after 8 days (B), showing elimination of nuclear
material (blue; H&E, C,D) and preservation of elastin (purple; EVG, G,H) but failure to
eliminate cellular material (yellow; SR, E,F). Scale bar C,E,G,=200 μm and D,F,H= 50 
μm. 
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Figure 4.4. Histological characterization of orbital shaker protocol-2. Schematic view of
the sample movement (A). Macroscopic appearance and histological analysis after
decellularization using an orbital shaker after 16 days (B), showing elimination of nuclear
material (blue; H&E, C,D) and preservation of elastin (purple; EVG, G,H) but failure to
eliminate cellular material (yellow; SR, E,F). Scale bar C,E,G,=200 μm and D,F,H= 50 
μm. 
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Subsequently, the g-force was increased up to 5-9g obtained by agitating the
tissue with a magnetic stirrer (protocol MS1). After 8 days of agitation the tissue
turned translucent (Figure 4.5B) and histological staining confirmed preservation
of collagen and elastin filaments, while nuclear materials were removed. This
latter finding was confirmed by DNA quantification which showed significant
reduction of DNA (p<0.001) and the amount of DNA was slightly below 50ng/mg
(Figure 4.6).
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Figure 4.5. Histological characterization of magnetic stirrer protocol. Schematic view of
the sample movement (A). Macroscopic appearance and histological images of
decellularized liver cubes using a magnetic stirrer after 8 days, showing complete
elimination of nuclear (blue; H&E, C,D) and cellular material (yellow; SR, E,F), and
preservation of elastin (purple; EVG, G,H). Scale bar C,E,G,=200 μm and D,F,H= 50 
μm. 
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Figure 4.6. DNA quantification comparison between native liver and decellularisation
protocols. The figure shows significant (p<0.0001) elimination of DNA in all
decellularization protocols, although all protocols were above the desired quantity of
50ng/mg.
Lastly, the applied g-force was further increased up to 45g in order to minimize
the time of exposure to detergents and to enhance the distribution of
reagents/solution within the tissue. Remarkably, the LTCs turned translucent in
just three hours (Figure 4.7A) in comparison to native tissue (Figure 4.2A). H&E
staining confirmed complete removal of nuclear materials (Figure 4.7 B,C) while
collagen and elastin filaments were preserved in the acellular liver tissue cube
(ALTC) as showed by SR and Elastin Van Gieson (EVG) staining, respectively
(Figure 4.7 D-G). Indeed, nuclei removal was confirmed by DNA quantification
showing a more evident reduction of the total amount of DNA compared
previously described protocols (p<0.001) (Figure 4.8 A). Collagen content relative
to wet weight was increased (p<0.01; Figure 4.8 B). These observations suggested
that by employing high flow shear stress it is possible to obtain, in a significant
reduced processing time, an ALTC with preserved collagen and elastin filaments
while cellular material was successfully removed.
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Figure 4.7. Histological characterization of high g-force protocol. Macroscopic
appearance and histological analysis after decellularization (A), confirmed elimination of
nuclear (blue; H&E, B,C) and cellular material (yellow; SR, D,E), preservation of
collagen (red; SR, D,E), and elastin (purple; EVG, F,G). Scale bar B,D,F = 200 μm and 
C,E,G= 50 μm. 
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Figure 4.8. DNA and collagen quantification comparison between native and
decellularised tissue by employing high-g force protocol. The figure shows significant
(p<0.0001) elimination of DNA in ALTCs (A). Collagen quantification of fresh liver
samples and ALTCs showing significant increase (p<0.01) in the total collagen content
after decellularization (B).
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4.3.2 ECM protein distribution and composition.
Next, the expression and distribution of the extracellular matrix (ECM) proteins in
ALTCs was analysed. Immunohistochemistry analysis showed that the expression
and distribution of key ECM components, namely collagen type I, collagen type
III, collagen IV, fibronectin and laminin (Figure 4.9) were maintained in ALTCs
when compared to native liver tissue.
Furthermore, the composition of ECM proteins within the ALTCs was
qualitatively investigated by proteomic analysis (Table 4.4). The protein score,
which reflects the sum of the ion scores of all peptides that were identified, was
increased for all proteins identified after decellularization when compared with
the native tissue.
Notably, the main fibrillar and structural collagens (collagen alpha-1,-3,-6) as well
as laminins were preserved after decellularization. In addition, other ECM
proteins were identified only within the acellular scaffold and were mainly
represented by proteoglycans (lumican and mimecan) and glycoprotein
(vitronectin).
In contrast to this, other ECM proteins were identified exclusively in the native
tissue such as laminin B1 and prelaminin-A/C.
Overall, this analysis confirmed the preservation of key ECM components in the
acellular scaffold.
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Figure 4.9. Immunohistochemistry of ECM proteins. Comparison of different ECM
protein expression and distribution evaluated by immunohistochemistry between
decellularized cubes (left panel) and fresh samples (right panel) showing preservation of
the ECM proteins after decellularization. Scale bar =100 μm.
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Table 4.4. Proteomic analysis of different ECM proteins in fresh liver samples and
ALTCs (A and B, respectively).
4.3.3 3D architecture and ultrastructure.
Scanning electron microscopy (SEM) was used to 1) compare native tissue
(Figure 4.10 A-C) with decellularized tissue as well as 2) to evaluate how the
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decellularization affected the micro-structure of the ECM (Figure 4.10 D-F). The
overall liver tissue micro-structure appeared maintained. Key architectural
structures such as portal tracts were recognised with their typical features and
distribution within the scaffold (Figure 4.10 D, asterisk). The areas corresponding
to the liver lobule were characterised by a three-dimensional network of
connective tissue fibres arranged in a honeycomb-like structure (Figure 4.10 E).
Most notably, the hepatocyte pocket was preserved and was surrounded by a
detailed network of ECM proteins (Figure 4.10 F). Overall, these data confirm the
preservation of the 3D liver microanatomy and ultrastructure following
decellularization.
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Figure 4.10. Ultrastructural characaterisation of native and decellularised liver. SEM
imaging of (A-C) fresh liver samples, and (D-F) decellularized liver cubes (asterisks
showing preservation of portal tract). Scale bars A,D = 100 m and B,C,E,F= 10 m.
Visualisation of the collagen type I organisation was conducted via second
harmonic generation (SHG) microscopy alongside multiphoton microscopy
(MPM) allowing autofluorescence from elastin to be visualised. Distinctly
differing organisation and distribution of collagen type I in the decellularized and
native tissue sections are seen through the SHG signal, with the decellularized
tissue containing more concentrated regions than the native tissue sections
probably due to the removal of cellular materials which outdistance the 3D
organisation of collagen fibres (Figures 4.11). Furthermore, regions on the
scaffold show areas where collagen fibres are aligned indicating stiffer regions
where there is reinforcement due to a more dense distribution of collagen. In
contrast, collagen observed in the native tissue sections is seen to predominantly
surround regions in the tissue that are indicated in the MPM signal. This indicates
that the decellularization procedure does not affect the hepatic 3D architecture
while collagen type I fibres appeared to be more concentrated and aligned due to
cellular removal.
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Figure 4.11. Second harmonic generation analysis of native and decellualarised liver. The
figure shows fibrillar collagens (green) structure of (A) fresh liver samples with the
presence of cells (red), (B) fresh liver samples with the subtraction of cells and (C)
ALTCs .
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4.3.4 Biochemical and biomechanical features of decellularized liver tissue.
Raman spectroscopy is an optical technique based on inelastic scattering of light
that can provide detailed molecular analysis of biological samples231. This
technique has a high chemical specificity as the shifts in the energy of laser
photons provide information regarding molecular vibrations in the sample. The
biochemical spectral Raman fingerprint has previously been used to detect tissue
pathology (e.g. cancer, fibrotic tissue) and to characterise the ECM generated
from tissue engineered constructs232,233.
The results obtained from confocal auto-fluorescence microscopy and Raman
spectral analysis on two ALTCs obtained in two independent experiments from
the same liver (Figure 4.12 A, B) showed tissue auto-fluorescence emission in the
wavelength between 450 – 480 nm when excited at 405 nm, which is an
indication of high content of collagen in the samples234. Furthermore, the confocal
fluorescence images allowed selection of areas for Raman spectroscopy
measurements. Areas of 4x4 mm2 were selected to ensure that spectral variations
due to sample heterogeneity are captured.
To understand the chemical composition of the samples, as well as variations
across the sample, the spectral maps were analysed using Principal Component
Analysis. The present pseudo-colour images based on the first six components
highlighted the overall morphology of the tissue samples (Figure 4.12 C, D). The
typical Raman spectra selected from each sample indicated strong fluorescence
emission (Figure 4.12 E, F). The Raman spectra were similar to Raman spectra of
collagen235, showing strong Raman bands at 851 cm-1 and 950 cm-1 assigned to
proline and hydroxyproline, 1004 cm-1 corresponding to phenylalanine, amide III
bands at 1246 cm-1, 1271 cm-1, CH2 deformations at 1450 cm-1 and Amide I at
1660 cm-1. However, due to the low signal-to-noise ratio, they cannot be used to
discriminate different types of collagen. Therefore, a K-means (k=3) clustering
method was applied to the entire dataset to understand the main spectral features.
The centroid spectra for both samples are illustrated in figure 4.13, which
represent the overall dominant bands of the samples including also the spectra
differences between A and B. It is worth noting that the two samples have similar
averaged spectra, with very low spectral differences. Furthermore, the Raman
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spectra indicate that no bands typically measured in the Raman spectra of cells
could be detected236.
Figure 4.12. Ramen spectroscopy analysis of two different ALTCs. (A, B) Confocal auto-
fluorescence microscopy showing preservation of the vascular trees. (C,D) Pseudo-colour
images based on the first six component, highlighting the overall morphology of the
ALTCs. (E, F) Raman spectra from different points on the cubes, showing similar spectra
pattern to collagen.
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Figure 4.13. Differences between Raman spectra of two different ALTCs. Biochemical
peaks of collagen proteins demonstrating no variability between the 2 different ALTCs.
Biomechanical characterisation of decellularized and native liver tissue was
conducted with atomic force microscopy (AFM). Calculation of the Young’s
modulus from the AFM force curves demonstrated a significant difference
(p<0.05) between the stiffness of decellularized liver tissue and the native tissue
(Figure 4.14). As previously published in other works related to biological
scaffolds 237, the Young’s modulus calculated for the decellularised liver tissue
was 2.051±0.39 kPa (SEM), around twice as great as that calculated for the native
liver tissue (0.98±0.14 kPa).
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Figure 4.14. Biomechanical properties of native and decellularised liver. Atomic Force
Microscopy (AFM) comparison of tissue stiffness between fresh and ALTCs.
4.3.5 Pro-angiogenic properties of acellular human liver scaffold
The chicken egg chorioallantoic membrane (CAM) assay was used to test in vivo
the ability of ALTCs to attract blood vessels (Figure 4.15 A-D). Fragments of
decellularized liver cubes were placed on the CAM and observed macroscopically
for 7 days. The scaffolds integrated well with the developing environment of the
chicken egg and representative images of ALTCs placed in ovo at 7 days of
incubation demonstrated attraction of blood vessels in a spoke-wheel pattern
(Figure 4.15 A). The effect of ALTCs on directed blood vessel growth was
quantified by counting the total number of blood vessels converging towards the
ALTCs. After 7 days from implantation the number of vessels growing towards
ALTCs was significantly increased in comparison to the same sample at day 0 and
to the membrane loaded with PBS that was used as a negative control (Figure 4.15
D, p<0.05). Interestingly, angiogenesis induced by the ALTCs 7 days post
implantation into the CAM, was also statistically higher than pro-angiogenic
cytokine VEGF-loaded membrane used as positive control (Figure 4D).
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Figure 4.15. Chorioallantoic membrane (CAM) assay. CAM assay of (A) decellularized
liver cube (B) sponge soaked in PBS, and (C) sponge soaked in VEGF. (D)
Quantification of observed vessels at 0 days and 7 days, showing a significant difference
between the decellularized liver cubes when compared to both sponges.
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4.3.6 Re-endothelization of acellular liver tissue cubes.
After testing the pro-angiogenic capabilities of ALTCs, we assessed the
recellularization of intra-hepatic vessels by employing human umbilical
endothelial vein cells (HUVECs). HUVECs were seeded into the ALTC and
engineered tissues were evaluated after 7 days of culture. After 7 days endothelial
cells were uniformly lining the luminal surface of large vessels (Figure 4.16 A-C).
In addition, the homogeneous expression of platelet endothelial cell adhesion
molecule (PECAM-1) (Figure 4.16 D-F) and FVIII confirmed the maintenance of
endothelial-like features (Figure 4.16 G-I).
Figure 4.16. Histological and immunohistochemical characterisation of recellularised
ALTCs with HUVECs, characterised by (A-C) H&E, (D-F) CD31 and (G-I) FVIII. Scale
bars A,C,D,F,G,I = 50 m or B,E,H = 200 m.
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4.3.7 Bioengineering of ALTCs scaffolds with human liver cell types
Next, the capability to repopulate the ALTCs with different hepatic cell types was
explored and evaluated after 7 and 14 days of in vitro culture. After 7 days of
seeding, HepG2 cells were found attached to the surface of the scaffold and
showed to repopulate the scaffold after 14 days, respectively (Figure 4.17 A, D).
HepG2 cells were characterized by an epithelioid phenotype as shown by SEM
and were diffusely spread and engrafted into the ECM scaffold (Figure 4.18).
Immunohistochemical staining revealed a strong positivity for alpha feto protein
(AFP) at 7 days which was sustained after 14 days of incubation (Figure 4.17 B,
E). In addition, cell adhesion within the acellular tissue was confirmed by a
sustained expression of the epithelial cell adhesion marker (EpCAM) at both 7
and 14 days (Figure 4.17 C, F). Moreover, the expression of human albumin and
the phase II metabolism enzyme UGT1A1 were evaluated in order to assess the
metabolic activity of the engrafted hepatocytes. Quantitative RT-PCR revealed
that the expression level of albumin was higher in the recellularized liver at 14
days when compared with a standard 2D culture, thus suggesting that the 3D
acellular tissue was able to maintain the differentiated phenotype for a longer time
period (Figure 4.19 A, p< 0.001 versus 2D culture). This finding was also
supported by higher level of expression in the recellularized liver of phase II
metabolism enzyme UGT1A1 at 14 days (Figure 4.19 B, p< 0.005 versus 2D
culture).
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Figure 4.17. Histological and immunohistochemical characterisation of recellularised
ALTCs with HepG2. Reseeded HepG2 were confirmed with (A,D) H&E staining and
expression of (B,E) AFP and (C-F) EPCAM at both 7 (left panel) and 14 days (right
panel).  Scale bars = 50 μm. 
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Figure 4.18. SEM image of engrafted Hepg2. The figure indicates epithelioid phenotype
after seeding in decellularised liver. Scale bars = 10 μm. 
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Figure 4.19. Gene expression analysis of engineered ALTCs with Hepg2. Quantitative
comparison of (A) albumin and (B) UGT1A1 gene expressions of HepG2 grown on 2D
plastic and those reseeded on decellularized liver cubes.
Similarly, H&E staining demonstrated the progressive engraftment of LX2 cells
into the scaffold after 14 days compared to 7 days (Figure 4.20 A, B). SEM
analysis further demonstrated that LX2 cells migrated within the decellularized
sinusoidal space acquiring a definite fibroblast-like cell phenotype (Figure 4.21).
The pro-fibrogenic phenotype of the cells migrated into the scaffold was assessed
by the expression of cellular markers typical of liver fibrosis39. The expression of
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key growth factor receptors such as platelet derived growth factor beta receptor
(PDGFβ-R) (Figure 4.20 C, D) and transforming growth factor beta receptor
(TGFβ-R) (Figure 4.20 E, F) was detected by immunohistochemistry. However, 
an interesting difference in the mRNA expression of two keys pro-fibrogenic
molecules, namely collagen type-1 and lysil oxydase (LOX) was observed by
comparing cells cultured in 3D-scaffolds versus standard 2D conditions. Indeed,
collagen type-1A1 expression was significant reduced in 3D culture (p<0.01)
(Figure 4.22 A) while LOX2 was significantly increased in cells cultured in 3D
conditions when compared with 2D culture (p<0.001) (Figure 4.22 B).
All together these findings demonstrated sufficient viability and function after
scaffold engineering.
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Figure 4.20. Histological and immunohistochemical characterisation of recellularised
ALTCs with LX2. Reseeded LX2 were confirmed with (A,D) H&E staining, and
expression of  (B,E) PDGFB-β and (C,F) TFG-β at both 7 (left panel) and 14 days (right 
panel).  Scale bars = 50 μm. 
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Figure 4.21. SEM image of engrafted LX2. The figure indicates fibroblast-like phenotype
after seeding in ALTCs. Scale bars = 10 μm. 
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Figure 4.22. Gene expression analysis of engineered ALTCs with LX2. Quantitative
comparison of (A) COL1A1 and (B) LOX gene expressions of LX2 grown on 2D plastic
and those reseeded on ALTCs.
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4.4 Discussion
This work demonstrates that small scale human liver biological scaffolds can be
derived by a process of agitation-decellularization employing high flow shear
stress (high g-force) which reduces processing time. The resultant 3D-human liver
scaffolds are characterized by the preservation of the essential biochemical,
physical and topographical properties and in addition can be engineered with
different types of human liver cells.
The field of agitation-decellularization was pioneered by Meezan and colleagues
in 1975153, who proposed this methodology for studying the basement membrane
microstructure. Subsequently, this methodology has been adapted to decellularize
sections of different tissues, including xenogenic liver, by incubating the native
tissue with different detergents without defining the mechanical forces109,124,133,140-
142,238.
A key contribution of the work described in this chapter is the development of a
novel decellularization protocol based on high g-force oscillation leading to the
successful removal of immunogenic cellular materials, while maintaining the
ECM protein composition and 3D architecture.
These results offer a key advance towards the use of whole healthy human livers
unsuitable for liver transplantation or wedges of resected liver tissue for
functional tissue engineering aimed at providing platforms for human disease
modelling and assessment of drug efficacy/toxicity.
Along these lines, a necessary step is represented by the ability of the
decellularized tissue to be repopulated by organ-specific cell types. Indeed, human
parenchymal (HepG2) and non-parenchymal (LX2) cell lines engrafted within the
human acellular liver tissue developed with the newly proposed protocol.
Although a successful engraftment was shown also with primary human
hepatocyte and hepatic stellate cells, the standardisation of the tissue engineering
protocol was obtained with the above mentioned cell lines in order to reduce the
variability inherent to the use of different isolates of primary human cells. The
expression of phenotype-specific markers for both human parenchymal and non-
parenchymal liver cells indicated that the engrafted cells maintain differentiation
and functionality. This was proven by the fact that HepG2 cells grown in 3D-
scaffolds were able to maintain higher cellular differentiation features following
151
prolonged culture when compared to the same cell preparation grown on standard
2D-plastic conditions.
Similarly, LX2 cells grown in 3D-scaffolds retained the phenotype of activated
cells. Importantly, the mRNA expression of key pro-fibrogenic genes (collagen
type-1 and LOX2) showed remarkable difference with the same cell preparation
grown on standard 2D-plastic conditions. These results underwrite the existence
of uncertainties on the accuracy and validity of target definition for a given
pathological process obtained by performing in vitro studies on artificial 2D
plastic systems.
Although small scale scaffolds cannot be perfused directly through the main
vasculature system, the ALTC maintain the vasculature structure and protein
composition of the native tissue. This was confirmed by demonstrating the
selective re-endothelization of human endothelial cells in ALTCs.
Altogether the current results provide an innovative basis for further
developments in the area of all human in vitro 3D-platforms for the study of
disease pathophysiology, pharmacological target discovery and drug toxicity
assessment.
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Chapter 5: Discussion and future work
Recent advances in the field of regenerative medicine hold promise for the
regeneration of different tissues and organs for clinical use. Tissue engineering of
simple structures such as bladder239, urethra240 and veins241 has already been
translated into important clinical applications. However research on more
complex parenchymal organs has been less extensive.
Before starting the work described in this thesis, there were no publications
demonstrating human liver tissue decellularisation. As outlined in Chapter 1, Paul
Lin et al. were the first to attempt animal liver tissue decellularisation in 2004 for
tissue engineering purpose124. In their experiments key functions of primary rat
hepatocytes seeded on (i) monolayer culture over absorbed collagen, (ii) cultured
between collagen gels and (ii) in decellularised porcine liver tissue scaffolds were
addressed.
They found that albumin and urea secretion (per viable cells) was significantly
higher in the decellularised porcine liver tissue scaffolds than in the other two
culture models, leading to the conclusion that biological scaffolds are superior to
other traditional techniques in preserving hepatocyte function. However, although
porcine livers are very similar to human livers in size, their ultrastructure differs
significantly.
Indeed, porcine livers have well defined lobules as they are outlined with
connective tissue. This connective tissue is absent in healthy human livers
between lobules and are only present in diseased livers (e.g. cirrhosis)242. There is
actually no animal liver with similar ultrastructure to human livers.
In the experiments concerning liver tissue engineering described in Chapters 2
and 4 it has been shown that an acellular natural matrix can be obtained from
human liver without disruption of the structural and mechanical characteristics of
the native tissue. The data described in this thesis provide a novel system capable
of effectively decellularising healthy human liver tissue cubes and whole human
livers156. This was achieved after employing and comparing previously described
protocols which were shown to be effective for the decellularisation of animal
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livers44-46,243,244. When compared to previously used methods, different
reagents/enzymes were used. However, the breakthrough in the methodology was
provided by the introduction of the retrograde perfusion (inflow from the central
vein) which was more effective for the homogenous removal of cellular materials
while preserving structural proteins, when compared with the antegrade system
(inflow from the portal vein). Initially, the removal of cellular debris and DNA
material was assessed both qualitatively and quantitatively. In addition, ECM
protein preservation was histologically compared and further
immunohistochemically analysed. Importantly, the resulting integrity of the
vascular network represents a key premise for the re-endothelialization and
reconstruction of the vascular network. In addition, the short time needed to
obtain the natural scaffold could have a positive impact for its clinical application.
The method described in Chapter 4 is definitely of relevance for liver tissue
bioengineering to be employed as a three-dimensional platform for drug testing
and biological assays in vitro as a complementary or alternative approach to
experimental animal models.
Indeed, the novel agitation-decellularisation protocol presented in Chapter 4 is an
innovative and effective matching the principles of the 3Rs, which are
replacement, refinement and reduction of animals in research. The mission of the
National Center for the Replacement, Refinement and Reduction of Animal
Research (NC3Rs), as stated on their website, is to “use the 3Rs principles to
accelerate scientific discovery, support innovation and technological
developments, and address societal concerns about animal research.” These
decellularised liver cubes would(i) accelerate scientific discovery, (ii) support
innovation and (iii) reduce and replace animal use in many scientific research.
Lastly, as described in Chapter 3 we have demonstrated that a 3D ECM scaffold
with a conserved vascular tree can be obtained from amyloidotic mouse liver with
retention of the natural structure and specific amyloidogenic properties of the
amyloid185. Decellularized amyloid organs provide an innovative experimental
model to further investigate the relationship between the ECM and amyloid
fibrils, including studies of the seeding effect of natural fibrils on amyloidogenic
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protein precursors perfused in vivo and characterization of possible effects of
natural amyloid fibrils on classical organ recellularization. High resolution, 3D
images of amyloid in its natural environment may also be informative about the
recently discovered putative expansive forces generated by fibril growth245.
Overall, the way to progress towards potential clinical applications should be
directed at: a) the evaluation of different protocols for recellularization by
employing perfusion bio-reactors allowing optimal cell homing when different
cell types are employed, either singularly or together; b) proteomic studies to
assess the preservation of ECM proteins and the presence of residual cellular
materials; c) the assessment of the metabolic requirements and functionality of
the bioengineered liver, d) an estimation of the accuracy of different types of cell
repopulation in reproducing 3D scenarios of liver pathophysiology fundamental
for liver disease modelling as well as for drug toxicity/efficacy testing, and e)
addressing ECM-disease associated biomarkers by performing proteomic
evaluation of decellularised tissues derived from livers with different background
of diseases.
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